REVIEW

Direct dopamine terminal regulation by local striatal microcircuitry

Suzanne O. Nolan[1] | Jennifer E. Zachry[1] | Amy R. Johnson[1] | Lillian J. Brady[1] |
Cody A. Siciliano[1,2,3] | Erin S. Calipari[1,2,3,4,5] (iD)

[1]Department of Pharmacology, Vanderbilt University, Nashville, TN, USA

[2]Vanderbilt Brain Institute, Vanderbilt University, Nashville, TN, USA

[3]Vanderbilt Center for Addiction Research, Vanderbilt University, Nashville, TN TN, USA

[4]Department of Molecular Physiology and Biophysics, Vanderbilt University, Nashville, TN, USA

[5]Department of Psychiatry and Behavioral Sciences, Vanderbilt University, Nashville, TN, USA

Correspondence
Erin S. Calipari, Assistant Professor, Department of Pharmacology, Department for Molecular Physiology and Biophysics, Department of Psychiatry and Behavioral Sciences, Vanderbilt Center for Addiction Research, Vanderbilt Brain Institute, Vanderbilt University, 865F Light Hall, 2215 Garland Avenue, Nashville, TN 37232, USA.
Email: erin.calipari@vanderbilt.edu

Abstract

Regulation of axonal dopamine release by local microcircuitry is at the hub of several biological processes that govern the timing and magnitude of signaling events in reward-related brain regions. An important characteristic of dopamine release from axon terminals in the striatum is that it is rapidly modulated by local regulatory mechanisms. These processes can occur via homosynaptic mechanisms—such as presynaptic dopamine autoreceptors and dopamine transporters - as well heterosynaptic mechanisms such as retrograde signaling from postsynaptic cholinergic and dynorphin systems, among others. Additionally, modulation of dopamine release via diffusible messengers, such as nitric oxide and hydrogen peroxide, allows for various metabolic factors to quickly and efficiently regulate dopamine release and subsequent signaling. Here we review how these mechanisms work in concert to influence the timing and magnitude of striatal dopamine signaling, independent of action potential activity at the level of dopaminergic cell bodies in the midbrain, thereby providing a parallel pathway by which dopamine can be modulated. Understanding the complexities of local regulation of dopamine signaling is required for building comprehensive frameworks of how activity throughout the dopamine system is integrated to drive signaling and control behavior.

1 | INTRODUCTION

Dopamine cell bodies in the midbrain send long-range projections to many targets in cortical and limbic structures allowing for dopaminergic modulation of neuronal function across the brain (Chen & Bonci, 2017; Russo & Nestler, 2013). The timing and magnitude of dopamine release is thought to relay information fundamental for guiding behavior, with functions ranging from encoding reward prediction error, to incentive value or even representations of an internal clock (Berridge, 2007; Meck, 2006; Schultz, Dayan, & Montague, 1997). Many facets of dopamine release are tightly controlled by a collection of receptor and transporter systems expressed at the presynaptic membrane. In the mesolimbic dopamine system, where dopamine is released from terminals in the nucleus accumbens (NAc), these include dopamine transporters (DAT) (Richardson, Saha, & Krout, 2016), dopamine type-2 autoreceptors (D2Rs) (Benoit-Marand, Ballion, Borrelli, Boraud, & Gonon, 2011), heteroreceptors (Zhang & Sulzer, 2012) including channels regulating ion flux (Brimblecombe, Gracie, Platt, & Cragg, 2015; Martel, Leo, Fulton, Bérard, & Trudeau, 2011) and nicotinic acetylcholine receptors (Grady et al., 2007), other signaling molecules such as nitric oxide (West, Galloway, & Grace, 2002), as well as steroid and sex hormones (Becker & Chart off, 2019). Direct regulation of dopamine release at the level of the terminal—through effectors located within or directly on dopamine terminals—is a critical component of dopamine release regulation and associated signaling.

The role of dopamine release is often discussed as an all-or-nothing process that compares how much dopamine is released relative to the baseline, ignoring the granularity of the signal regarding how the magnitude, spread, and duration is shaped by the local microenvironment. These properties likely contain critical information that extends far beyond just the relative peak concentration of release events. The contribution of local microcircuitry is fundamental in regulating the timing of signaling, both pre- and post-synaptic, as well as the interactions between basal dopamine levels and stimulus-dependent signaling downstream. When accounting for these factors in sum, dopaminergic microcircuitry allows for a robust dynamic range in signal events, and therefore there is likely more complex and nuanced information encoded within these signaling domains. Here we review the current research on the complex mechanisms regulating the dynamics of dopamine release at its projection targets in the striatum. Ultimately, mechanisms that elicit and shape dopamine release at the terminal may represent novel avenues for therapeutic interventions targeting striatal dopamine dysregulation in disease and as such an understanding of these regulatory mechanisms is critical to moving the field forward.

2 | HOMOSYNAPTIC REGULATION AT THE TERMINAL

Dopamine terminals in reward-related brain regions, such as the NAc are regulated by a number of transmitters supplied by local neurons (heterosynaptic—see section 3) or through responses to dopamine itself (homosynaptic—discussed in the present section). In this section, we will discuss the three following critical processes that govern release magnitude and temporal dynamics: (1) alterations in release probability and release pool dynamics (2) autoreceptor-mediated feedback mechanisms, and (3) changes in the function and expression levels of transporters controlling dopamine reuptake and repackaging. These processes all work to modulate the magnitude, onset, and duration of dopamine levels in the extracellular space.

2.1 | Regulation of dopamine release

Early observations demonstrated that a single vesicle filled with neurotransmitter molecules represents the elementary unit of synaptic transmission (Katz, 1971). However, more recent work has shown that the magnitude of release events the central nervous system can be modulated by a number of factors, including neurotrophic factors and neurotransmitter synthesis (Pothos, Davila, & Sulzer, 1998; Pothos et al., 2000). Thus, the regulation of dopamine release is a potent mechanism by which dopamine terminals can be regulated. One common mechanism that impacts the magnitude and onset of dopamine release is related to changes in release mechanisms within the terminal itself, including changes in the distribution of various vesicle pools (section 2.1.1) and changes in the conductance or expression of calcium channels on presynaptic dopamine terminals (section 2.1.2) (Figure 1a). Plasticity in these mechanisms may allow for differential transformations between upstream action potential activity and downstream release, both across time/experience and between distinct terminals arising from the same soma.

2.1.1 | Vesicle pool effects

Dopamine is released from multiple separate pools or compartments (del Castillo & Katz, 1954; Ewing, Bigelow, & Wightman, 1983; Javoy & Glowinski, 1971). These pools can most simply be divided into three distinct pools: the readily releasable pool, the recycling pool and the reserve pool (Rizzoli & Betz, 2005).

Readily releasable pool
The readily releasable pool contains recently synthesized dopamine and is released first following activation by action potentials (Besson, Cheramy, Feltz, & Glowinski, 1969). The structure of this pool ensures immediate exocytosis of neurotransmitter in response to depolarization in the fast-acting synapse, though the magnitude of the pool will decline in response to continued activity. However, this pool can be quickly refilled from the other pools of dopamine (Yavich & MacDonald, 2000). Plasticity in this refilling process does indeed occur, as evidence showed that high-frequency stimulation repeated at 5 second intervals significantly delayed this decline in the magnitude of dopamine release (Stevens & Wesseling, 1998; Wang & Kaczmarek, 1998). This effect is perhaps because of increased rate of refill from the reserve compartment, which has been proposed

FIGURE 1 Homosynaptic and heterosynaptic regulators of presynaptic dopamine release in the striatum. Dopamine release at the terminal can be elicited and modulated through mechanisms intrinsic to the cell itself, as well as via substrates released from postsynaptic cells and presynaptic inputs from non-dopaminergic systems. (a) Fluctuations in the functionality of transporters, changes in the size of the various vesicle pools and activity of autoreceptors - all termed homosynaptic regulators - each have established roles in determining the amplitude of evoked dopamine release events. (b) Several neurotransmitters from local microcircuitry, such as glutamate (Zhang & Sulzer, 2003), GABA (Brog et al., 1993; Pennartz et al., 1994), dynorphin (Britt & McGehee, 2008; Thompson et al. 2000), and acetylcholine (Collins et al., 2016; Kosillo et al., 2016; Shin et al., 2017; Yorgason et al., 2017), as well as diffusible retrograde signaling molecules like hydrogen peroxide (Chen et al., 2001) and nitric oxide (Kiss et al., 1999) can all exert influences on dopamine release at the axon terminal. ACh, acetylecholine; ChAt, choline acetyltransferase; DAT, dopamine transporter; GABA-R, GABA receptor (there is a lack of clarity as to which subtypes - GABA-A (ionotropic) or GABA-B (metabotropic) - are located on terminals and a single receptor is denoted here for simplicity); Glu, glutamate; IR, insulin receptor; KOR, kappa opioid receptor; nAChR, nicotinic acetylcholine receptor; NO, nitric oxide; mGluR, metabotropic glutamate receptor; MSN, medium spiny neuron; SST, somatostatin; PV, paralbumin; VMAT, vesicular monoamine transporter

for other types of synapses (Richards, Guatimosim, Rizzoli, & Betz, 2003). Previous work has shown that multiple psychostimulants can elicit increased dopamine release via mobilization of secondary reserves of dopamine (Shore, 1976; Venton et al., 2006). Furthermore, the distribution of dopamine between the different pools may be related to individual differences in responding for cocaine (Verheij & Cools, 2011; Verheij, de Mulder, De Leonibus, van Loo, & Cools, 2008). This dopamine mobilization by cocaine is synapsin- and DAT-dependent (Kile et al., 2010; Venton et al., 2006). Importantly, in non-dopaminergic systems, calcium signaling has been demonstrated to play a role in the upregulation of release magnitude through docking of reserve pool vesicles following priming events (Thanawala & Regehr, 2013; Wang, Pinter, & Rich, 2016) an effect that may play a similar role in dopaminergic terminals.

At glutamatergic synapses, plasticity processes like LTD have been shown to be related to decreases in the readily releasable pool (Goda & Stevens, 1998). Additionally, inhibition of the mammalian

target of rapamycin (mTOR), which plays a role in activity-dependent plasticity, within the presynaptic bouton has been shown to induce the formation of autophagic vacuoles which sequester and degrade dopamine-containing vesicles, thereby providing another mechanism for decreasing the size of the pool and subsequent release (Schmitz, Benoit-Marand, Gonon, & Sulzer, 2003). Ultimately, the releasable pool is maintained by both synthesis and reuptake-dependent vesicular repackaging, and therefore is inextricably linked with other presynaptic agents, such as transporters and synthesis/degradation enzymes (section 2.3).

Recycling pool

The recycling pool consists of a mobile pool of dopamine, composing roughly 10-20% of available dopamine (Denker & Rizzoli, 2010; Rizzoli & Betz, 2005). This pool exists to meet the high demand of the cell, as *de novo* synthesis of vesicles from the soma is a much slower process (Chanaday, Cousin, Milosevic, Watanabe,

& Morgan, 2019). However, it should be noted that more recent studies indicate that the distinctions between the recycling pool and the reserve pool are less clear, proposing that vesicles eventually mature from the recycling pool to the reserve pool over a discrete period of time (Denker & Rizzoli, 2010; Kamin et al., 2010). This maturation process then sets up the possibility that this recycling process may then be involved in aspects of terminal plasticity.

Reserve pool

Finally, it is also important to consider the reserve pool. The reserve pool represents the largest pool of dopamine, consisting of roughly 80-90% of the available dopamine. These reserve pools are regulated by the synapsin protein family, the loss of which prevents cocaine augmentation of dopamine release following long simulations (Venton et al., 2006). Facilitation of shifting from the reserve pool to the active zone of the terminal is thought to be dependent on calcium influx, as well as actin polymerization status via interactions with alpha-synuclein (Bellani et al., 2010). The size of the reserve pool is a key determinant in establishing release magnitude following long stimulation paradigms. Moreover, effects on the reserve pool may underlie part of the physiological response to psychostimulants, as long duration stimulation of the dorsal striatum has been shown to elicit reduced dopamine release after administration of amphetamine (Covey, Juliano, & Garris, 2013).

Together, these studies demonstrate that the distribution of dopamine between the different vesicle pools is one of several dynamic processes that allows for regulation of release. Indeed, shifts in the release pool distribution that are important for release have been shown to occur when there are perturbations in dopamine clearance mechanisms (Jones et al., 1999), and may in fact serve as a compensatory mechanism following persistent stimulation and/or uptake blockade (as would be seen with stimulant use (Calipari et al., 2014)), or simply a way to shift release efficiency following different experiences. However, the precise conditions that result in release pool distribution shifts are not well understood and require further study.

2.1.2 | Calcium regulation of dopamine release

Calcium entry into the bouton through voltage-gated calcium channels bears the primary responsibility of initiating synaptic transmission at conventional synapses. These channels interact functionally with other ion channels to modulate release (Martel et al., 2011). This is a key process that can be regulated via numerous mechanisms to enhance release. For example, calcium channels can be enhanced via upregulated expression levels or via changes in conductance. Furthermore, the relationship between terminal depolarization and neurotransmitter release can change over repeated stimulations, an effect that is driven by changes in the sensitivity of calcium-binding proteins for calcium itself, also altering the relationship between

calcium and exocytotic release (Hsu, Augustine, & Jackson, 1996). Together, these mechanisms allow for experience-dependent plasticity in calcium systems that are critical for neurotransmitter release.

Significant heterogeneity exists in the presence of channel types and function at the dopaminergic terminal across various brain areas (Brimblecombe et al., 2015). There are multiple types of calcium channels, many of which have differential effects on dopamine terminals and dopamine release. Regarding dopamine regulation, N-Type (CAV2.2) have the largest effect on dopamine release where blocking these channels almost completely eliminates evoked dopamine release from terminals in the ventral striatum (Brimblecombe et al., 2015; Phillips & Stamford, 2000). P/Q-type (CAV2.1) calcium channels are also a critical regulators of dopamine release, where blocking these channels significantly reduces release, but does not completely abolish it. Blocking T-type channels modestly reduces release, but much smaller than the previously mentioned subtypes. Finally, it is likely that L-type calcium channels (CAV1.2/1.3/1.4) are present on dopamine terminals in the NAc, though pharmacological blockade has no effect on dopamine release in slice voltammetry experiments (Brimblecombe et al., 2015), which calls into question their functional role in direct release regulation as well as presence directly on dopamine terminals. Importantly, all calcium channels present on the membrane of terminals are capable of regulating calcium flux through posttranslational modifications, such as those that can alter conductance or more broadly via expression; thus, implicating these channels as potential mediators of experience-dependent plasticity at dopamine synapses. In addition to CAV 1.2, 1.3, 1.4, 2.1, and 2.2, TRP channels are also potent regulators of calcium signaling and have been suggested to have a role in plasticity within this circuit (Fowler, Sidiropoulou, Ozkan, Phillips, & Cooper, 2007; Wescott, Rauthan, & Xu, 2013). The ability to regulate calcium following experience-dependent plasticity is critical for release, given the clear relationship between the size of the readily releasable pool and calcium (Thanawala & Regehr, 2013).

Calcium regulation of release through voltage gated calcium channels is a critical step in action potential-dependent release; however, calcium-dependent regulation of intracellular signaling and release can also occur through a variety of ligand-gated receptors that are permeable to calcium. For example, some nicotinic acetylcholine receptors are highly calcium permeable (Lendvai & Vizi, 2008; Séguéla, Wadiche, Dineley-Miller, Dani, & Patrick, 1993). Therefore, it is conceivable that any changes in nicotinic receptor density or subunit composition resulting from plasticity mechanisms or sex-dependent effects may be related to changes in calcium influx in the terminal resulting from acetylcholine binding and associated channel opening. Broadly, these heterosynaptic receptor mechanisms are described in more detail below (section 3), and these findings indicate that they may serve as a critical component of release regulation via modulation of calcium influx into dopamine terminals.

Together, interactions between releasable pool organization, calcium dynamics, and release machinery all interact to alter the magnitude of dopamine release events directly at terminal projections in the striatum. This is a critical component allowing for release to

scale, allowing for a dynamic system that can change on a rapid or prolonged time scale.

2.2 | Autoreceptor-mediated feedback mechanisms

In addition to calcium channels, release can also be regulated via G-protein coupled receptors that are located on dopamine terminals. This group of receptors is comprised of both heteroreceptors (described in detail in section 3) and autoreceptors. D2Rs are autoreceptors that provide inhibitory feedback to curtail signaling at times of heightened extracellular dopamine levels, thereby profoundly regulating both the temporal dynamics of extracellular dopamine levels and the magnitude of evoked dopamine release events. Of the receptors expressed on dopamine terminals in the striatum, D2Rs are among the most studied and have been well characterized. They are located both at the level of the cell-body in the ventral tegmental area (VTA) as well as directly on terminals in striatal regions where they act to downregulate tyrosine hydroxylase (TH) expression and cellular activity, leading to decreases in dopamine production and release (Anzalone et al., 2012; Benoit-Marand et al., 2011; Benoit-Marand, Borrelli, & Gonon, 2001; Ford, 2014; Kennedy, Jones, & Wightman, 1992; Palij et al., 1990; Phillips, Hancock, & Stamford, 2002; Rouge-Pont et al., 2002; Schmitz, Schmauss, & Sulzer, 2002). Mechanistically, these receptors are G_i-coupled and early work showed that D2R-mediated decreases in dopamine neuron excitability occur via activation of inwardly rectifying potassium (K^+) channels—both GIRK and Kv channels—and via inhibiting P/Q and N-type calcium channels (Cardozo & Bean, 1995). However, more recent work has shown that while D2R-activation may alter calcium currents, the effects on calcium currents are downstream of initial K^+ channel effects (Congar, Bergevin, & Trudeau, 2002). Indeed, there is a wealth of evidence demonstrating that the ability of D2Rs to reduce terminal dopamine release occurs through functional interactions with K^+ channels, as D2R-mediated reductions in dopamine overflow can be attenuated by bath application of Kv1.1/1.2/1.6 blockers, with a smaller role played by interactions with GIRK channels (Congar et al., 2002; Fulton et al., 2011; Martel et al., 2011). Additionally, D2R activation results in observable increases in Kv1.2 mediated currents, and germline loss of Kv1.2 as well as selective blockage of Kv1.2 prevent D2R-mediated dopaminergic release regulation further highlighting the role that potassium channels play in this process (Fulton et al., 2011).

Aside from acute regulation of terminal excitability and associated release, activation of D2Rs has been shown to drive posttranslational modifications to other regulators, such as DAT and vesicular monoamine transporter-2 (VMAT2), leading to lasting alterations in transporter function and associated repackaging efficiency (Belin, Deroche-Gamonet, & Jaber, 2007; Meiergerd, Patterson, & Schenk, 1993), an effect that alters the timing of dopamine release. Similarly, chronic activation of D2Rs can also induce morphological changes in dopaminergic axon growth and alterations in plasticity across multiple striatal subregions (Fasano, Kortleven,

& Trudeau, 2010; Giguère et al., 2019; Parish, Finkelstein, Drago, Borrelli, & Horne, 2001; Parish et al., 2002; Tripanichkul, Stanic, Drago, Finkelstein, & Horne, 2003). These changes have important implications for subsequent terminal release events and dopamine-mediated plasticity of other cell types across the brain as well.

2.2.1 | Region-specific D2 regulation

D2Rs are critical regulators of dopamine release across the entire striatum; however, their efficacy in reducing dopamine release has been shown to differ depending on the striatal subregion. D2Rs are most efficacious at reducing dopamine release in dorsal striatal regions and their efficacy reduces in a stepwise function from dorsolateral striatum down to medial shell (Rothblat & Schneider, 1997). However, it should be noted that this observation has been contested by more recent studies, which demonstrate that D2 agonists have similar inhibitory effects in the dorsal striatum, NAc core and NAc shell (Holloway et al., 2019; Maina & Mathews, 2010). Region-specificity in function may be because of interactions with other regulators mentioned here, as recent evidence has highlighted that activation of D2Rs in the dorsal striatum, but not the ventral striatum, increases DAT phosphorylation and surface trafficking (Gowrishankar et al., 2018). Taken together, this potential heterogeneity provides a region-specific regulatory mechanism allowing for different relationships between release dynamics and timing between regions—an effect that may allow for region-specific behavioral regulation.

2.3 | Changes in the function and expression levels of transporters

One of the most critical regulators of dopamine signaling is the speed at which it is cleared from the extracellular space and repackaged for future release events. Below we outline how transport regulation plays a key role in dopamine terminal regulation through the major regulators of this process: DAT and VMAT2.

2.3.1 | Dopamine transporter

Mounting evidence has demonstrated that DAT represents a critical regulator of terminal release and plasticity via regulation of the temporal dynamics of dopamine in the extracellular space (Condon, Platt, & Zhang, 2019). DAT is a low capacity, high affinity transporter expressed on dopamine neurons and can be found on dopamine cell bodies, their dendrites, and their axonal projections (Ciliax et al., 1995; Freed et al., 1995). It is comprised of 12 transmembrane domains with both the N- and C-terminus located intracellularly (Giros & Caron, 1993; Uhl & Kitayama, 1993). DAT is a member of the Na+/Cl- transporter family and uses the Na + concentration gradient created by the Na+/K + ATPase to transport dopamine from

the extracellular space to the intracellular space. In the striatum, DAT is the primary method of clearing dopamine from the extracellular space (Chen & Reith, 2000; Giros, Jaber, Jones, Wightman, & Caron, 1996; Jones et al., 1998). As such, any changes in DAT expression or function can have profound consequences on the timing and duration of dopamine's interactions with receptors after release events.

DAT is a target of many psychotropic drugs such as cocaine, methamphetamine, and amphetamine (Baumann et al., 2012; Belovich et al., 2019; Cartier et al., 2015; Hamilton et al., 2014; Rothman et al., 2001) and therefore has been well-studied for its role in substance use disorder, motivation, and dopamine signaling. Impaired clearance, resulting from inhibition of DAT by compounds such as cocaine, produces elevated levels of dopamine in the extracellular space for prolonged periods of time, and consequently increases postsynaptic dopamine receptor activation on target cells. Similar findings have been reported with other approaches such as genetic downregulation of DAT, where mice lacking the DAT showed elevated extracellular dopamine and an extended half-life of dopamine in the extracellular space. Importantly, these mice also had a decreased releasable pool of dopamine despite an elevated rate of dopamine synthesis (Jones et al., 1998), highlighting the critical role that DAT plays in vesicular repackaging. Thus, DAT is involved not only in clearance rates, but also facilitates packaging dopamine into vesicles by both bringing released dopamine back into the presynaptic cell and facilitating its repackaging into vesicles through interactions between specific synaptic vesicle proteins and the N-terminus of the DAT (Egaña et al., 2009).

The N and C termini of DAT can both be post-translationally modified to alter its membrane stability and function (Belovich et al., 2019; Cartier et al., 2015; Hamilton et al., 2014; Sweeney, Tremblay, Stockner, Sitte, & Melikian, 2017). Protein kinase C (PKC) has been shown to phosphorylate the DAT, cause internalization, and decrease transport kinetics (Foster, Adkins, Lever, & Vaughan, 2008; Loder & Melikian, 2003; Moritz et al., 2015). PKC activity is also involved in amphetamine-mediated dopamine efflux along with CaMKII, Akt, and PI-3 kinase (Fog et al., 2006; Wei et al., 2007). While phosphorylation of DAT by PKC can decrease DAT activity, phosphorylation by other kinases such as extracellular signal-related kinase 1 and 2 (ERK1/2) can increase DAT activity (Morón et al., 2003). The phosphatases PP1 and PP2A associate with DAT and are responsible for dephosphorylation of specific phosphorylation sites on the DAT (Foster et al., 2012). Furthermore, inhibition of PP2A activity decreases dopamine uptake (Bauman et al., 2000). All of the above effectors—ERK, PKC, PP1, PP2A, CaMKII, Akt, and phosphoinositide 3-kinase (PI3K)—are directly linked to activity-dependent signaling, providing a potential mechanism by which changes in terminal excitability can regulate clearance on a rapid timescale. Indeed, changes in membrane potential alter DAT membrane expression and dopamine clearance via rapid DAT trafficking on a second timescale, through interactions Rit2 (Fagan, Kearney, & Sweeney, 2020; Richardson et al., 2016; Sweeney et al., 2020). Additionally, increasing dopamine neuron activity increased phosphorylated-ERK, DAT

phosphorylation at threonine53 (known to be phosphorylated by ERK), and leads to functional increases in DAT-mediated dopamine clearance rates (Calipari, Juarez, et al., 2017).

Several receptors are also involved in regulating DAT function and expression. For example, DAT has direct protein-protein interactions with the D2R and co-expression of D2Rs increases DAT membrane expression and subsequent uptake in cultured neurons (Lee et al., 2007; Mayfield & Zahniser, 2001). However, conditional loss of the D2R in dopamine neurons does not alter dopamine kinetics (Giguère et al., 2019). These data suggest that the D2R-mediated mechanisms can regulate DAT function quickly and transiently, but D2Rs are not necessary for basal DAT activity. The activation of κ-opioid receptors (KORs) also increases dopamine uptake through DAT regulation (Thompson et al., 2000) while activation of metabotropic glutamate receptor 5 (mGluR5) receptors decreases the maximal rate of dopamine update (V_{max}) (Page, Peeters, Najimi, Maloteaux, & Hermans, 2001), suggesting that G_i (KOR) and G_q (mGluR5)-mediated signaling exert opposing actions on DAT-mediated clearance rates.

2.3.2 | Region-specific DAT regulation

DAT expression, like D2Rs, shows region-specific effects on dopamine signaling. Dopamine clearance is highest in dorsal striatal regions and clearance rates decrease across a gradient from dorsolateral striatum down to medial shell. This region-specific DAT regulation is important as psychostimulant drugs, which inhibit transporter function, can have region-specific efficacy. For example, the effects of amphetamine are largest in the dorsal striatum because of the higher density of DAT in the region (Ramsson, Howard, Covey, & Garris, 2011; Siciliano, Calipari, & Jones, 2014).

2.3.3 | Vesicular monoamine transporter-2 (VMAT2)

While DAT clears dopamine from the extracellular space, VMAT2 clears dopamine from the cytosolic space and sequesters it into synaptic vesicles (Erickson, Eiden, & Hoffman, 1992; Liu et al., 1992). This serves two important functions: 1) by sequestering dopamine in vesicles it protects the cell from free radicals produced during enzymatic degradation of dopamine by monoamine oxidases in the cytosol (Liu & Edwards, 1997; Liu et al., 1992) and 2) it allows the dopamine to be recycled and to be prepared for re-release. This transporter has 12 transmembrane domains with N- and C-terminals in the cytosol and several potential sites for posttranslational modification, including phosphorylation and glycosylation sites (Schuldiner, Shirvan, & Linial, 1995). This transporter relies on the H^+ gradient created by the H^+ ATP-ase, which works to sequester H^+ ions in the vesicles and create a proton gradient. Conversely, VMAT2 functions as an antiporter, transporting 2 H^+ molecules out of the vesicle for each dopamine molecule it transports into the vesicle [VMAT2 function reviewed in (Eiden & Weihe, 2011)].

Inhibition of VMAT2 function via pharmacological methods, such as application of reserpine, leads to decreases in quantal dopamine release (Floor, Leventhal, Wang, Meng, & Chen, 1995; Pothos et al., 1998). Increases in VMAT2 expression or function results in increased dopamine loading into vesicles which leads to increases in quantal release of dopamine as well as increases in the number of release events, providing a critical role for VMAT2 in regulating the amount of dopamine released in the extracellular space (Eiden & Weihe, 2011; Lohr, Bernstein, & Stout, 2014; Lohr et al., 2015; Pothos et al., 2000). Along similar lines, multiple studies have shown that expression of VMAT2 is required for vesicular dopamine storage, with VMAT2 deficient mice showing significantly reduced dopamine release depending on the relative levels of VMAT expression (Mooslehner et al., 2001; Patel, Mooslehner, Chan, Emson, & Stamford, 2003; Wang et al., 1997). Acute blockade of VMAT2 function with reserpine also diminishes dopamine release as measured by voltammetry, suggesting that this blockade significantly prevents pool refilling (Kuhr, Bigelow, & Wightman, 1986). Additionally, expression of VMAT2 can be regulated in an activity-dependent manner and function can be altered by N-terminal glycosylation by CREB (Watson, Kiernan, Deavall, Varro, & Dimaline, 2001; Yao, Erickson, & Hersh, 2004)(Watson et al., 2001; Yao et al., 2004). Thus, VMAT2 regulation also represents a critical factor that dictates the amount of stimulus-dependent dopamine release and can allow for dynamic changes as cellular activity changes.

Taken together, transporters exert important effects on the functioning of the dopamine terminals. They exert strong influence over extracellular and intracellular dopamine levels, releasable pool volume, release magnitude, and duration of dopamine's presence in the extracellular space.

3 | HETEROSYNAPTIC REGULATION AT THE TERMINAL

In addition to homosynaptic mechanisms that regulate dopamine release independent of other local circuitry, there is complex microcircuitry in the NAc whereby ligands can be released from non-dopaminergic populations and bind to receptors located directly on the dopamine terminal (Figure 1b). In addition to the dopamine terminals originating from the VTA that are described above, the striatum contains several types of postsynaptic neurons including GABAergic medium spiny projection neurons as well as a diverse population of interneurons (e.g. parvalbumin, somatostatin, cholinergic). Regulation of the levels of released ligands—via changes in the excitability of interneuron populations—along with regulation of the expression and function of the receptors for these ligands can dynamically influence the magnitude and frequency of synaptic dopamine release. Below we review the regulators that directly influence release at dopamine terminals through monosynaptic connections—that is, via transmitters/molecules that signal through receptors/effectors that are located directly on or within dopamine terminals.

3.1 | GPCRs and ligand-gated ion channels

Dopamine terminals in the striatum express several classes of heteroreceptors that can be classified as ligand-gated ionotropic receptors or G-protein coupled receptors (GPCRs). Ligand-gated receptors—such as nicotinic acetylcholine receptors (nAChRs) (Quik, Bordia, & O'Leary, 2007), and GABA-A receptors (Brodnik, Batra, Oleson, & España, 2019)—bind to neurotransmitter an allow for the passage of ions that can increase or decrease release probability and terminal excitability. Similarly, GPCRs located on terminals can also alter release, membrane excitability, function of transporters, and dopamine synthesis (Huang & Thathiah, 2015) through initiation of intracellular cascades that can cause a variety of effects, including increases or decreases in cAMP production, opening of inward rectifying potassium channels that cause hyperpolarization, changes to kinase function and increases or decreases in gene expression. Dopamine terminals express many classes of GPCRs, including: D2Rs (Chesselet, 1984; Ford, 2014), kappa opioid receptors (KOR) (Ronken, Mulder, & Schoffelmeer, 1993a; Svingos, Chavkin, Colago, & Pickel, 2001), GABA-B receptors (Lopes, Roberts, Siddorn, Clements, & Cragg, 2019; Ronken et al., 1993a), as well as metabotropic glutamate receptors (mGluR) (Kuwajima et al., 2007; Manzoni, Michel, & Bockaert, 1997). Generally, these receptors can be classified as excitatory or inhibitory based on the second messenger system they activate. Receptors that couple to excitatory G proteins—G_s or G_q—tend to increase activity of the cell by increasing cAMP production, increasing calcium levels, and increasing gene expression (Huang & Thathiah, 2015). Conversely, receptors that couple to inhibitory G proteins—$G_{i/o}$—tend to decrease the activity of the cell by inhibiting cAMP production, activating GIRK channels (and/or other inwardly rectifying channels), inhibiting calcium channels, and increasing or decreasing gene expression. Below we outline ligand-gated receptors and GPCRs that have been shown to directly regulate dopamine release at terminals:

3.1.1 | κ-opioid receptors (KORs)

Another major regulator of dopamine release occurs via KORs. These GPCRs are located on dopamine terminals and act as a negative regulator of dopamine release through direct G_i signaling cascades that affect release probability and dopamine synthesis, as well as through interactions with the DAT that alter clearance rates (Britt & McGehee, 2008; Thompson et al., 2000). Dynorphin, the endogenous ligand of KORs, is released from postsynaptic D1 receptor containing medium spiny neurons (MSNs) and acts to reduce dopamine release when high levels of D1 MSN activation occur. To this end, terminals can be regulated via changes in local dynorphin tone in an experience-dependent fashion. For example, repeated drug exposure and stress have both been shown to alter both dynorphin levels as well as KOR regulation—effects that converge to regulate tonic dopamine levels within the synapse (Bruchas, Land, & Chavkin, 2010; Crowley & Kash, 2015;

Karkhanis, Rose, Huggins, Konstantopoulos, & Jones, 2015; Karkhanis, Rose, Weiner, & Jones, 2016; Land et al., 2008).

Region-specific KOR regulation. Additionally, like with other regulatory mechanisms, expression of these receptors follows a region specificity, such that the NAc shell displays a "patchy" or clustered expression pattern (Mansour et al., 1994; Svingos, Colago, & Pickel, 1999), while the caudate-putamen shows dense expression in the medial and ventral portion (Steiner & Gerfen, 1996, 1998). When total receptor availability or functional effects on dopamine release are compared, studies have found greater KOR availability/function within the NAc compared to dorsal regions of the striatum, an effect that has been demonstrated in both rodents and non-human primates (Le Merrer, Becker, Befort, & Kieffer, 2009; Siciliano et al., 2015).

3.1.2 | Metabotropic glutamate receptors (mGluRs)

While it is well-known that glutamate has robust actions on dopamine signaling within the striatum, how exactly glutamate exerts these actions has been a matter of controversy. Early work showed that exogenous application of L-glutamic acid increased spontaneous release of dopamine in striatal slices, though whether this was mediated through ionotropic or metabotropic receptors is unclear (Giorguieff, Kemel, & Glowinski, 1977). Local infusion of a glutamate reuptake inhibitor into the NAc resulted in increased extracellular dopamine in the NAc of rats as measured by microdialysis (Segovia & Mora, 2001), which is consistent with human imaging studies (Gleich et al., 2015). Exactly which receptors were present on dopamine terminals was a matter of much debate until electron microscopy confirmed the presence of mGluR1a on dopaminergic terminals (Paquet & Smith, 2003). In line with this evidence, previous work has shown that intrastriatal injection of the mGluR group I and II agonist 1*S*,3*R*-ACPD results in a behavioral phenotype that can be directly correlated with increased tissue levels of dopamine and its metabolites (Sacaan, Bymaster, & Schoepp, 1992). However, there are limited studies that have outlined the precise mechanisms by which these receptors directly regulate dopamine release. Work from Sulzer and colleagues has shown that blockade of glutamatergic uptake in slice decreases dopamine release through mGluR1 activation through a mechanism involving phospholipase C and activation of calcium-dependent potassium channels (Zhang & Sulzer, 2003). Interestingly, this glutamate appears to come from spillover from nearby corticostriatal glutamatergic synapses (Zhang & Sulzer, 2003). The localization of these receptors on dopamine terminals and subsequent activation provides yet another potential mechanism by which glutamatergic inputs into the striatum may be able to directly regulate dopamine terminals independent of local microcircuitry.

3.1.3 | GABA receptors

There are a variety of sources of GABA within the striatum including parvalbumin and somatostatin interneurons as well as GABAergic MSNs (Brog, Salyapongse, Deutch, & Zahm, 1993; Pennartz, Groenewegen, & Lopes da Silva, 1994). Locally released GABA acts to reduce dopamine release, either through G_i-coupled GABA-B receptors or ionotropic GABA-A receptors (Brodnik et al., 2019; Pitman, Puil, & Borgland, 2014; Ronken, Mulder, & Schoffelmeer, 1993b). Indeed, effects on dopamine release can occur through either GABA-A and GABA-B receptors as agonism of either receptor subtype reduces dopamine release (Brodnik et al., 2019; Pitman et al., 2014). However, GABA-A receptor-mediated reductions in dopamine release can be blocked with a GABA-B receptor antagonist, suggesting that GABA-A effects occur through a polysynaptic mechanism, rather than through direct effects on terminals (Brodnik et al., 2019). Thus, striatal GABA can inhibit dopamine release through both GABA-A and GABA-B receptors; however, there is some debate as to the localization of these receptors on local circuitry and terminals (Brodnik et al., 2019; Lopes et al., 2019; Pitman et al., 2014).

3.1.4 | Nicotinic acetylcholine receptors

One of the most studied circuits in regard to local striatal regulation of dopamine release is acetylcholine release from cholinergic interneurons and the associated activation of nAchRs. nAchRs are pentameric ligand-gated ionotropic receptors that are activated by the endogenous ligand acetylcholine and are also the primary site of action for the exogenous ligand nicotine. As such these local circuit regulation mechanisms have been of interest in our understanding of substance use disorder, and much of our basic understanding of this process has originated from studies investigating how nicotinic agonists and antagonists affect dopamine release (Cachope et al., 2012; Collins, Aitken, Greenfield, Ostlund, & Wassum, 2016; Fennell, Pitts, Sexton, & Ferris, 2019; Kosillo, Zhang, Threlfell, & Cragg, 2016; Lim, Kang, & McGehee, 2014; Shin, Adrover, & Alvarez, 2017; Threlfell et al., 2012; Yorgason, Zeppenfeld, & Williams, 2017). In the striatum, dopamine is released in tonic (slow and regular) and phasic (short, burst/spikes) frequency patterns (Liss & Roeper, 2010) that are subject to heavy modulation by these cholinergic systems (Rice & Cragg, 2004). Normally, when increasing electrical stimulation frequencies are applied to dopamine terminals in brain slices, the total amount of dopamine release stays relatively stable; however, when acetylcholine is blocked by a nAchR antagonist, dopamine release is robustly responsive to stimulation frequency (Rice & Cragg, 2004; Zhang & Sulzer, 2004). These results have led to the hypothesis that acetylcholine in the striatum acts as a low-pass filter at dopamine terminals. In other words, in basal conditions where tonic acetylcholine is present high frequencies stimulations are "filtered out", but when acetylcholine is blocked or reduced via endogenous mechanisms, this filter is lifted (Rice & Cragg, 2004; Zhang & Sulzer, 2004).

The above examples focus on how signaling through nAchRs can alter dopamine release; however, these effects are beginning to be further characterized based on the type and location of nAchRs in the striatum. nAchRs have a number of subtypes, and as such, the

expression and subunit composition of nAChRs on dopamine terminals is of vast importance to activity-dependent regulation of dopamine neurotransmission (Threlfell & Cragg, 2011). Neuronal nAChRs are composed of combinations of any of the 10 alpha (α2−α10) and 3 beta (β2−β4) subunits (Karlin, 1993, 2002; McGehee & Role, 1995). Each receptor is composed of 5 of these subunits, typically in a heteromeric composition, though homomeric arrangements also exist. Thus, there are a large number of possible compositions which can vary greatly in their physiological and biophysical properties (Lim et al., 2014). Within the NAc, the most commonly expressed receptors contain α4, α6, α7, β2 and β3 (Quik et al., 2007) and are most often broadly divided into two groups that are either α6 or non- α6 containing (Salminen et al., 2004; Threlfell & Cragg, 2011).

These subtypes of nAChRs can confer different biophysical properties, which adds further complexity in addition to differences in cell-type specific expression in the striatum. nAChRs have been shown to be located on cholinergic interneurons (Azam, Winzer-Serhan, & Leslie, 2003), glutamatergic terminals in the NAc (Marchi, Risso, Viola, Cavazzani, & Raiteri, 2002), cell bodies of GABAergic interneuronal populations (Inoue, Suzuki, Nishimura, & Miura, 2016), and dopaminergic terminals (Champtiaux et al., 2003; Lim et al., 2014). The β2 subunit is thought to be expressed in all nAChRs on dopamine terminals within the striatum, and has been shown to be important for the rewarding effects of nicotine (Picciotto et al., 1998). Moreover, the activation of these specific receptors enhances dopamine release via a calcium-dependent mechanism, showing their ability to directly alter effectors necessary for dopamine release and associated plasticity (Turner, 2004). Importantly, α6β2 subunit containing nAChRs located on dopamine terminals have been shown to mediate differential behavioral and physiological responses to nicotine (Fennell et al., 2019; Siciliano, McIntosh, Jones, & Ferris, 2017). Therefore, the type of nAChR subunits present plays a particularly critical role in the direct modulation of dopamine release via acetylcholine release.

3.1.5 | Heterosynaptic regulation of calcium flux

While we discussed calcium channels as homosynaptic regulators of dopamine release above, it is important to also note that many ligand-gated ion channels also often are highly permeable to calcium. Thus, calcium regulation via either homosynaptic or heterosynaptic mechanisms plays a significant role in activity-dependent dopamine release dynamics. In particular, nAChRs and NMDARs (another ligand-gated receptor) have both been demonstrated to be permeable to calcium (MacDermott, Mayer, Westbrook, Smith, & Barker, 1986). In fact, recent work showed that calcium entry through nAChRs leads to enhanced size of the ready releasable pool, which can subsequently result in increased quantal dopamine release (Turner, 2004). Similarly, early work has shown that NMDA receptor activation can trigger dopamine release in the striatum, which may be mediated by increased calcium flux into the terminal, rather than other direct mechanisms (discussed in section 2.1.2) (Cheramy, Godeheu,

L'Hirondel, & Glowinski, 1996; Krebs, Kemel, Gauchy, Desban, & Glowinski, 1989; Krebs et al., 1991). Thus, modifications in calcium entry and synaptic regulation of this process can also play a critical role in regulating dopamine release dynamics across the striatum.

3.2 | Heterosynaptic transport mechanisms: Organic cation transporter

The organic cation transporter 3 (OCT3) is a high capacity, low affinity transporter located on dopamine neurons (Mayer et al., 2018), surrounding non-dopaminergic neurons and astrocytes (Cui, Aras, & Christian, 2009) that plays a smaller role than DAT in clearing dopamine from the extracellular space, but nonetheless does participate in dopamine temporal dynamics. OCT3 is a low affinity, high capacity transporter, meaning that it does not efficiently bind dopamine but has the capacity to transport large amounts of substrate. Functionally, this transporter works to reduce excess extracellular dopamine to prevent toxicity and oxidative stress (Cui et al., 2009). Inhibition of this transporter by the steroid hormone corticosterone can affect dopamine transients in vivo and can extend effects of DAT-inhibitor drugs like cocaine (Graf et al., 2013). Other hormones, including gonadal hormones like 17β-estradiol (E2) and progesterone, may inhibit this transporter (Iversen & Salt, 1970) but in vivo studies have not yet been conducted to determine if these effects occur in live animals. These hormonal effects point to the possibility of potential sex differences, however there is a surprising paucity of data regarding hormonal action on microcircuit regulation of dopamine dynamics.

Importantly, the ability of both steroid and sex hormones to selectively alter clearance through modulation of secondary uptake mechanisms provides an avenue for dopamine regulation in a context-specific fashion. Because low affinity transporters like OCT3 are only engaged in situations where there is high concentration of extracellular dopamine, this likely only plays a strong role in regulating dopamine signaling in certain situations (e.g. high intensity stimuli or drug effects) but not others (basal dopamine release). Thus, these mechanisms are likely more complicated than simply increasing or decreasing extracellular dopamine levels, and therefore understanding dopamine regulation moving forward will require an understanding of context-specific processes.

3.3 | Non-canonical regulatory mechanisms: diffusible transmitters and hormones

In addition to modulation by the neurotransmitter mediated- and clearance-based mechanisms, there are several diffusible signaling mechanisms that play potent roles in modulating dopamine release, including nitric oxide, hydrogen peroxide (H_2O_2), and insulin. These signaling molecules, especially for hormonal control, allow for state-dependent regulation of dopamine release to modify signal transduction in different cellular environments.

3.3.1 | Nitric oxide regulation of dopamine transmission

Nitric oxide is produced by a variety of neurons throughout the brain and its production is stimulated by elevated intracellular calcium levels through a calmodulin-dependent process [reviewed in (Vincent, 2010)]. However, these neurons densely innervate neighboring neurons, supporting potential involvement of nitric oxide in the regulation of many systems, including dopamine terminals in the NAc. Indeed, sodium nitroprusside, which generates nitric oxide, dose-dependently increases the amount of [3H]-dopamine released from pre-loaded dopamine terminals (Hanbauer, Wink, Osawa, Edelman, & Gally, 1992), and slows [3H]-dopamine uptake rates measured in striatal synaptosomes (Pogun, Baumann, & Kuhar, 1994). Furthermore, administration of nitric oxide synthase inhibitors, which reduce nitric oxide production, decreases striatal dopamine release (Kiss, Hennings, Zsilla, & Vizi, 1999), showing that the effects of nitric oxide are bidirectional. This relationship remains true for [3H]-dopamine electrically evoked from intact terminals in striatal slices (Sandor, Brassai, Pliskas, & Lendvai, 1995). It has been suggested that some of the effects of nitric oxide occur via direct inhibition of DAT, thereby slowing clearance to increase synaptic dopamine levels (Kiss et al., 1999; Kiss 2000). Indeed, the effects of nitric oxide on dopamine release can be blocked by nomifensine, a potent DAT inhibitor (Kiss et al., 1999). Together, this provides a potent mechanism by which activity-dependent regulation of postsynaptic neurons can cause significant plasticity to dopamine terminals to alter feedforward signaling in this circuit following activity—and associated calcium influx—in postsynaptic cells.

3.3.2 | Hydrogen peroxide (H_2O_2) modulation of dopamine dynamics

The enzymatic breakdown of dopamine and other monoamine neurotransmitters results in the production of several by-products, including reactive oxygen species such hydrogen peroxide (H_2O_2). While atypical production of reactive oxygen species is considered a harmful effect of oxidative cellular stress, under normal physiological conditions these species can also serve as important diffusible chemical messengers. Early work in the hippocampus deduced that H_2O_2 may inhibit release via inactivation of presynaptic ion channels (Pellmar, 1987). Similarly, within the dopaminergic terminal, endogenous production of H_2O_2 inhibits presynaptic dopamine release through a calcium-dependent mechanism (Chen, Avshalumov, & Rice, 2001). H_2O_2 is generated from enzymatic reactions within medium spiny neurons and results in retrograde signaling that inhibits terminal dopamine release through ATP-sensitive potassium channels (Rice, 2011). More recent work, leveraging approaches to monitor fluctuations in H_2O_2 and dopamine release concurrently has also demonstrated H_2O_2-induced inhibition of dopamine release in dorsal striatum (Spanos et al., 2013). Thus, H_2O_2 along with nitric oxide represent two diffusible molecules that are generated in the

postsynaptic cells in the striatum that function as potent retrograde regulators of dopamine terminals.

3.3.3 | Insulin

In addition to the other receptors mentioned within this review, the NAc also expresses a high density of insulin receptors which function to regulate the reinforcing aspects of food intake through direct modulation of dopamine terminals (Fordahl & Jones, 2017; Stouffer et al., 2015; Werther et al.., 1987). Circulating levels of insulin have indeed been shown to bidirectionally modify dopamine dynamics, through interactions with DAT and through DAT trafficking mechanisms. In normal/basal states, insulin activates PI3 kinase (PI3K), leading to increases in dopamine uptake rates (Carvelli et al., 2002), an effect that leads to more efficient repackaging of dopamine. However in low-glucose states, for example following chronic food restriction, low circulating insulin levels are concomitant with reduced dopamine uptake rates—thus prolonging the time that dopamine is present in the synaptic cleft following release (Zhen, Reith, & Carr, 2006). Dietary manipulations that lead to insulin resistance have shown a similar phenotype (Fordahl & Jones, 2017). Similarly, glucose clearance rate is negatively correlated with dopamine clearance rates (Fordahl & Jones, 2017) and this effect can be reversed by dose-dependent bath application of insulin (Fordahl & Jones, 2017), indicating that the effects of insulin on dopamine dynamics are rapid and direct. Other lines of research have shown that insulin also reduces somatodendritic dopamine release in the VTA, providing a mechanism that also influences terminal DA release (Mebel, Wong, Dong, & Borgland, 2012; Naef, Seabrook, Hsiao, Li, & Borgland, 2019).

Thus, in addition to canonical regulatory mechanisms through neurotransmitter systems, a number of diffusible signaling molecules and hormones act directly on dopamine terminals to alter dopamine signaling in response to both internal states (hunger, satiety) and following experience-dependent post-synaptic plasticity. These mechanisms serve as a process by which dopamine release, repackaging, and clearance can be modulated on either a rapid or prolonged timescale to influence how incoming upstream signals induce dopamine release and associated downstream signaling.

4 | OTHER CANDIDATE DIRECT MECHANISMS

The sections above have outlined the receptor systems present directly on dopamine terminals that allow for direct monosynaptic regulation of dopamine release dynamics. However, there are a number of other systems that show robust dopamine terminal regulation independent of VTA activity—and as such may exert direct control; yet many of these effects have been debated to be through other indirect polysynaptic mechanisms and require further analysis to definitively define their circuit localization.

One important candidate mechanism concerns ionotropic glutamate receptors, such as the NMDA receptor, and whether they can directly modulate presynaptic dopaminergic terminal. Indeed, early work using push-pull cannulae and superfusion slice methods showed that activation of NMDA receptors resulted in increased dopamine release in the striatum (Cheramy et al., 1996; Krebs et al., 1989, 1991). More recent work using in vivo voltammetric recordings demonstrated that intra-striatal infusion of an NMDA receptor antagonist reduces dopamine release (Borland & Michael, 2004; Kulagina, Zigmond, & Michael, 2001). However, ex vivo application of NMDA receptors agonists also reduced evoked accumbal dopamine release (Wu, Pearl, Zigmond, & Michael, 2000; Yavas & Young, 2017), an effect that is blocked by application of an NMDAR antagonist. These opposing effects—where in vivo and ex vivo application of an antagonist and agonists have the same effect on dopamine release—suggest that there may be multiple circuit-based mechanisms responsible for these effects, and it has been suggested that these effects are unlikely to be mediated by direct modulation of terminal excitability (Yavas & Young, 2017). A prominent theory is that NMDAR activation increases local glutamate spillover and leads to subsequent regulation of dopamine terminals through either activation of metabotropic glutamate receptors and/or cholinergic interneurons (Zhang & Sulzer, 2003). Data suggest that both metabotropic glutamate receptors and nAChRs are key mediators of NMDAR-mediated effects, as antagonism of both receptors blocked NMDAR effects (Marchi & Grilli, 2010; Zhang & Sulzer, 2003). However, it is also possible that NMDAR activation increases in the activity of local cholinergic interneurons and acetylcholine release then activates nAChRs directly on dopamine terminals. However, activation of nAChRs negatively regulates the effect of NMDAR agonists on dopamine release via triggering internalization of NMDA receptors that are located directly on the dopaminergic terminals themselves, suggesting NMDA effects likely wok through other mechanisms (Salamone et al., 2014).

Neurotensin is a signaling peptide that binds to the G-protein coupled receptor neurotensin receptor 1 and plays a role in regulating synaptic plasticity in the dopaminergic system (Binder, Kinkead, Owens, & Nemeroff, 2001; White et al., 2012). These receptors are present on both cell bodies in the VTA and substantia nigra, as well as presynaptically in the dorsal and ventral portions of the striatum (Nicot, Rostene, & Berod, 1994; Palacios & Kuhar, 1981; Quirion, Chiueh, Everist, & Pert, 1985; Schotte & Leysen, 1989). With respect to presynaptic release regulation, exogenous application of neurotensin has been shown to potentiate evoked dopamine release in NAc slices (Hetier, Boireau, Dubedat, & Blanchard, 1988). More recent voltammetric studies showed that phasic stimulation of dopaminergic terminal concurrent with exogenous neurotensin application results in augmented dopamine release (Fawaz, Martel, Leo, & Trudeau, 2009). However, the effects are only observed with voltammetric recordings following multiple pulse, but not single pulse, stimulations. This is important to note as multiple pulse stimulation paradigms in ex vivo voltammetric studies allow for the recruitment of indirect circuit mechanisms, while single pulse stimulations

largely isolate direct terminal effects. Thus, it is clear that neurotensin has potent regulatory effects on dopamine terminals in striatal regions; however, it is unclear whether this effect is monosynaptic or polysynaptic.

5 | EXPANDING OUR UNDERSTANDING OF DOPAMINE RELEASE REGULATION

Taken together, there are complex regulatory mechanisms that control dopamine release at the level of the terminal. The microcircuit mechanisms described here allow for encoding of important information that may extend computations beyond just the amount of relative release and may control differential dopamine release within microdomains. Indeed, there is evidence for differential dopamine release regulation and clearance kinetics within genetically defined patch and matrix compartments, even within a single defined region like the NAc core (Brimblecombe & Cragg, 2017; Jiménez-Castellanos & Graybiel, 1989; Nastuk & Graybiel, 1985; Shu, Taylor, & Michael, 2013). Thus, moving forward it will be critical to understand how different release regulation that is driven by these monosynaptic connections alters behavior and signaling in unique ways.

One important caveat is that a large majority of this work was conducted in male animals, despite seminal work showing significant local effects of gonadal hormones within mesolimbic systems (Anker & Carroll, 2011; Bazzett & Becker, 1994; Becker, 1999; Carroll & Smethells, 2015; Cummings, Jagannathan, Jackson, & Becker, 2014; Lynch, Roth, & Carroll, 2002; Walker, Ray, & Kuhn, 2006; Walker, Rooney, Wightman, & Kuhn, 2000; Yoest, Quigley, & Becker, 2018). It should be noted that much of the work in males was conducted in *ex vivo* preparations which isolates the local circuits, and as such is advantageous for investigating direct mechanisms without confounding influences of long-range projection systems and other whole animal systems such as circulating hormones. However, it is difficult to disentangle how the organizational effects of sex may influence local microcircuitry and interact with the mechanisms described above. Along these lines, there is significant evidence of differences in distribution and size of dopamine cell bodies between the sexes, even early in development, suggesting that dopaminergic systems are at least in part differentially organized (Ovtscharoff, Eusterschulte, Zienecker, Reisert, & Pilgrim, 1992). Studies to explicitly test whether the reviewed mechanisms are present in females, the microcircuits are organized the same way between the sexes, or whether they affect dopamine release to a similar extent in both sexes have not been completed to date. Furthermore, while work has focused on how sex interacts with aspects of substance use (Siciliano, 2019; Townsend, Negus, Caine, Thomsen, & Banks, 2019), depression (Ma, Xu, Wang, & Li, 2019), motivation, and the dopaminergic mechanisms underlying these phenotypes (Becker & Koob, 2016; Johnson et al., 2019; Kutlu et al., 2020), it remains mostly unclear how sex interacts with the specific local terminal regulatory mechanisms outlined in this review to drive these behaviors. Taken

12 | **WILEY**— Journal of Neurochemistry JNC *The Official Journal of the International Society for Neurochemistry*

NOLAN ET AL.

together, lack of understanding of how terminal dopamine is modulated in both males and females will further impede the development of pharmaceuticals to many neuropsychiatric conditions involving dopamine dysfunction, including substance use disorder (Correa-De-Araujo, 2006).

Finally, there has been a significant body of work that has sought to link dopamine to its role in motivated behavior, and as such, has supported dopamine's role in reinforcement learning, motivation, and disorders associated with these behaviors (Ahmed, 2018; Berke, 2018; Berridge, 2012; Dayan, 2009; Keiflin & Janak, 2015; Watabe-Uchida, Eshel, & Uchida, 2017). However, discerning the exact contributions of the above described microcircuit mechanisms to dopamine release events during learning has remained elusive because of technical limitations. Early studies conducted using microdialysis methods, provided valuable insights but lacked the resolution to dissociate effects on dopamine release that occurred directly at the dopamine terminal from effects upstream in the VTA. Still other studies have utilized transgenic mouse lines (Lammel et al., 2015) or blocked entire receptor systems (Mahler et al., 2019; Roberts, Corcoran, & Fibiger, 1977), both of which make it difficult to disentangle cell body mechanisms from terminal regulation. While the VTA to NAc projection is intimately involved with reward learning, activity in this circuit can result in an array of dopamine release mechanisms—reviewed above, and how these distinct mechanisms contribute to learning processes has yet to be established. Moreover, the variety of mechanisms and resulting dopamine signal may differentially encode aspects of contingencies, and as such, achieving a precise understanding how these microcircuits evoke dopamine and in what specific contexts they are invoked is critical to understanding how this release impacts downstream signaling and achieves behavioral control.

CONFLICT OF INTEREST

The authors have no conflicts to report.

ORCID

Erin S. Calipari (iD) https://orcid.org/0000-0003-4723-0623

REFERENCES

Ahmed, S. H. (2018). Trying to make sense of rodents' drug choice behavior. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, *87*, 3–10. https://doi.org/10.1016/j.pnpbp.2017.09.027

Anker, J. J., & Carroll, M. E. (2011). Females are more vulnerable to drug abuse than males: Evidence from preclinical studies and the role of ovarian hormones. *Current Topics in Behavioral Neurosciences*, *8*, 73–96.

Anzalone, A., Lizardi-Ortiz, J. E., Ramos, M., De Mei, C., Hopf, F. W., Iaccarino, C., ... Borrelli, E. (2012). Dual control of dopamine synthesis and release by presynaptic and postsynaptic dopamine D2 receptors. *Journal of Neuroscience*, *32*, 9023–9034. https://doi.org/10.1523/JNEUROSCI.0918-12.2012

Azam, L., Winzer-Serhan, U., & Leslie, F. M. (2003). Co-expression of alpha7 and beta2 nicotinic acetylcholine receptor subunit mRNAs within rat brain cholinergic neurons. *Neuroscience*, *119*, 965–977.

Bauman, A. L., Apparsundaram, S., Ramamoorthy, S., Wadzinski, B. E., Vaughan, R. A., & Blakely, R. D. (2000). Cocaine and anti-depressant-sensitive biogenic amine transporters exist in regulated complexes with protein phosphatase 2A. *Journal of Neuroscience*, *20*, 7571–7578. https://doi.org/10.1523/JNEUROSCI.20-20-07571.2000

Baumann, M. H., Ayestas, M. A., Partilla, J. S., Sink, J. R., Shulgin, A. T., Daley, P. F., ... Cozzi, N. V. (2012). The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue. *Neuropsychopharmacology*, *37*, 1192–1203. https://doi.org/10.1038/npp.2011.304

Bazzett, T. J., & Becker, J. B. (1994). Sex differences in the rapid and acute effects of estrogen on striatal D2 dopamine receptor binding. *Brain Research*, *637*, 163–172. https://doi.org/10.1016/0006-8993(94)91229-7

Becker, J. B. (1999). Gender differences in dopaminergic function in striatum and nucleus accumbens. *Pharmacology, Biochemistry and Behavior*, *64*, 803–812.

Becker, J. B., & Chartoff, E. (2019). Sex differences in neural mechanisms mediating reward and addiction. *Neuropsychopharmacology*, *44*, 166–183. https://doi.org/10.1038/s41386-018-0125-6

Becker, J. B., & Koob, G. F. (2016). Sex differences in animal models: Focus on addiction. *Pharmacological Reviews*, *68*, 242–263. https://doi.org/10.1124/pr.115.011163

Belin, D., Deroche-Gamonet, V., & Jaber, M. (2007). Cocaine-induced sensitization is associated with altered dynamics of transcriptional responses of the dopamine transporter, tyrosine hydroxylase, and dopamine D2 receptors in C57Bl/6J mice. *Psychopharmacology (Berl)*, *193*, 567–578. https://doi.org/10.1007/s00213-007-0790-3

Bellani, S., Sousa, V. L., Ronzitti, G., Valtorta, F., Meldolesi, J., & Chieregatti, E. (2010). The regulation of synaptic function by α-synuclein. *Communicative and Integrative Biology*, *3*, 106–109.

Belovich, A. N., Aguilar, J. I., Mabry, S. J., Cheng, M. H., Zanella, D., Hamilton, P. J., ... Galli, A. (2019). A network of phosphatidylinositol (4,5)-bisphosphate (PIP(2)) binding sites on the dopamine transporter regulates amphetamine behavior in Drosophila Melanogaster. *Molecular Psychiatry*. https://doi.org/10.1038/s41380-019-0620-0

Benoit-Marand, M., Ballion, B., Borrelli, E., Boraud, T., & Gonon, F. (2011). Inhibition of dopamine uptake by D2 antagonists: An in vivo study. *Journal of Neurochemistry*, *116*, 449–458. https://doi.org/10.1111/j.1471-4159.2010.07125.x

Benoit-Marand, M., Borrelli, E., & Gonon, F. (2001). Inhibition of dopamine release via presynaptic D2 receptors: Time course and functional characteristics in vivo. *Journal of Neuroscience*, *21*, 9134–9141.

Berke, J. D. (2018). What does dopamine mean? *Nature Neuroscience*, *21*, 787–793. https://doi.org/10.1038/s41593-018-0152-y

Berridge, K. C. (2007). The debate over dopamine's role in reward: The case for incentive salience. *Psychopharmacology (Berl)*, *191*, 391–431. https://doi.org/10.1007/s00213-006-0578-x

Berridge, K. C. (2012). From prediction error to incentive salience: Mesolimbic computation of reward motivation. *European Journal of Neuroscience*, *35*, 1124–1143. https://doi.org/10.1111/j.1460-9568.2012.07990.x

Besson, M. J., Cheramy, A., Feltz, P., & Glowinski, J. (1969). Release of newly synthesized dopamine from dopamine-containing terminals in the striatum of the rat. *Proceedings of the National Academy of Sciences of the United States of America*, 62, 741–748.

Binder, E. B., Kinkead, B., Owens, M. J., & Nemeroff, C. B. (2001). Neurotensin and dopamine interactions. *Pharmacological Reviews*, 53, 453–486.

Borland, L. M., & Michael, A. C. (2004). Voltammetric study of the control of striatal dopamine release by glutamate. *Journal of Neurochemistry*, 91, 220–229. https://doi.org/10.1111/j.1471-4159.2004.02708.x

Brimblecombe, K. R., & Cragg, S. J. (2017). The striosome and matrix compartments of the striatum: A path through the labyrinth from neurochemistry toward function. *ACS Chemical Neuroscience*, 8, 235–242. https://doi.org/10.1021/acschemneuro.6b00333

Brimblecombe, K. R., Gracie, C. J., Platt, N. J., & Cragg, S. J. (2015). Gating of dopamine transmission by calcium and axonal N-, Q-, T- and L-type voltage-gated calcium channels differs between striatal domains. *Journal of Physiology*, 593, 929–946. https://doi.org/10.1113/jphysiol.2014.285890

Britt, J. P., & McGehee, D. S. (2008). Presynaptic opioid and nicotinic receptor modulation of dopamine overflow in the nucleus accumbens. *Journal of Neuroscience*, 28, 1672–1681. https://doi.org/10.1523/JNEUROSCI.4275-07.2008

Brodnik, Z. D., Batra, A., Oleson, E. B., & España, R. A. (2019). Local GABAA receptor-mediated suppression of dopamine release within the nucleus accumbens. *ACS Chemical Neuroscience*, 10, 1978–1985.

Brog, J. S., Salyapongse, A., Deutch, A. Y., & Zahm, D. S. (1993). The patterns of afferent innervation of the core and shell in the "accumbens" part of the rat ventral striatum: Immunohistochemical detection of retrogradely transported fluoro-gold. *The Journal of Comparative Neurology*, 338, 255–278. https://doi.org/10.1002/cne.903380209

Bruchas, M. R., Land, B. B., & Chavkin, C. (2010). The dynorphin/kappa opioid system as a modulator of stress-induced and pro-addictive behaviors. *Brain Research*, 1314, 44–55. https://doi.org/10.1016/j.brainres.2009.08.062

Cachope, R., Mateo, Y., Mathur, B. N., Irving, J., Wang, H.-L., Morales, M., ... Cheer, J. F. (2012). Selective activation of cholinergic interneurons enhances accumbal phasic dopamine release: Setting the tone for reward processing. *Cell Reports*, 2, 33–41. https://doi.org/10.1016/j.celrep.2012.05.011

Calipari, E. S., Ferris, M. J., Melchior, J. R., Bermejo, K., Salahpour, A., Roberts, D. C., & Jones, S. R. (2014). Methylphenidate and cocaine self-administration produce distinct dopamine terminal alterations. *Addiction Biology*, 19, 145–155. https://doi.org/10.1111/j.1369-1600.2012.00456.x

Calipari, E. S., Juarez, B., Morel, C. et al (2017). Dopaminergic dynamics underlying sex-specific cocaine reward. *Nature Communications*, 8, 13877.

Cardozo, D. L., & Bean, B. P. (1995). Voltage-dependent calcium channels in rat midbrain dopamine neurons: Modulation by dopamine and GABAB receptors. *Journal of Neurophysiology*, 74, 1137–1148. https://doi.org/10.1152/jn.1995.74.3.1137

Carroll, M. E., & Smethells, J. R. (2015). Sex differences in behavioral dyscontrol: Role in drug addiction and novel treatments. *Frontiers in Psychiatry*, 6, 175.

Cartier, E., Hamilton, P. J., Belovich, A. N., Shekar, A., Campbell, N. G., Saunders, C., ... Galli, A. (2015). Rare autism-associated variants implicate syntaxin 1 (STX1 R26Q) phosphorylation and the dopamine transporter (hDAT R51W) in dopamine neurotransmission and behaviors. *EBioMedicine*, 2, 135–146. https://doi.org/10.1016/j.ebiom.2015.01.007

Carvelli, L., Morón, J. A., Kahlig, K. M., Ferrer, J. V., Sen, N., Lechleiter, J. D., ... Galli, A. (2002). PI 3-kinase regulation of dopamine uptake. *Journal of Neurochemistry*, 81, 859–869. https://doi.org/10.1046/j.1471-4159.2002.00892.x

Champtiaux, N., Gotti, C., Cordero-Erausquin, M., David, D. J., Przybylski, C., Léna, C., ... Changeux, J.-P. (2003). Subunit composition of functional nicotinic receptors in dopaminergic neurons investigated with knock-out mice. *Journal of Neuroscience*, 23, 7820–7829. https://doi.org/10.1523/JNEUROSCI.23-21-07820.2003

Chanaday, N. L., Cousin, M. A., Milosevic, I., Watanabe, S., & Morgan, J. R. (2019). The synaptic vesicle cycle revisited: New insights into the modes and mechanisms. *Journal of Neuroscience*, 39, 8209–8216. https://doi.org/10.1523/JNEUROSCI.1158-19.2019

Chen, B. T., Avshalumov, M. V., & Rice, M. E. (2001). H2O2 is a novel, endogenous modulator of synaptic dopamine release. *Journal of Neurophysiology*, 85, 2468–2476.

Chen, B. T., & Bonci, A. (2017). The Mesocortical Dopaminergic System. *The Human Frontal Lobes: Functions and Disorders*, 13.

Chen, N., & Reith, M. E. (2000). Structure and function of the dopamine transporter. *European Journal of Pharmacology*, 405, 329–339.

Cheramy, A., Godeheu, G., L'Hirondel, M., & Glowinski, J. (1996). Cooperative contributions of cholinergic and NMDA receptors in the presynaptic control of dopamine release from synaptosomes of the rat striatum. *The Journal of Pharmacology and Experimental Therapeutics*, 276, 616–625.

Chesselet, M. F. (1984). Presynaptic regulation of neurotransmitter release in the brain: Facts and hypothesis. *Neuroscience*, 12, 347–375. https://doi.org/10.1016/0306-4522(84)90058-7

Ciliax, B. J., Heilman, C., Demchyshyn, L. L., Pristupa, Z. B., Ince, E., Hersch, S. M., ... Levey, A. I. (1995). The dopamine transporter: Immunochemical characterization and localization in brain. *Journal of Neuroscience*, 15, 1714–1723. https://doi.org/10.1523/JNEUROSCI.15-03-01714.1995

Collins, A. L., Aitken, T. J., Greenfield, V. Y., Ostlund, S. B., & Wassum, K. M. (2016). Nucleus accumbens acetylcholine receptors modulate dopamine and motivation. *Neuropsychopharmacology*, 41, 2830–2838. https://doi.org/10.1038/npp.2016.81

Condon, M. D., Platt, N. J., Zhang, Y.-F. et al (2019). Plasticity in striatal dopamine release is governed by release-independent depression and the dopamine transporter. *Nature Communications*, 10, 4263.

Congar, P., Bergevin, A., & Trudeau, L. E. (2002). D2 receptors inhibit the secretory process downstream from calcium influx in dopaminergic neurons: Implication of K^+ channels. *Journal of Neurophysiology*, 87, 1046–1056.

Correa-De-Araujo, R. (2006). Serious gaps: How the lack of sex/gender-based research impairs health. *Journal of Women's Health*, 15, 1116–1122. https://doi.org/10.1089/jwh.2006.15.1116

Covey, D. P., Juliano, S. A., & Garris, P. A. (2013). Amphetamine elicits opposing actions on readily releasable and reserve pools for dopamine. *PLoS ONE*, 8, e60763. https://doi.org/10.1371/journal.pone.0060763

Crowley, N. A., & Kash, T. L. (2015). Kappa opioid receptor signaling in the brain: Circuitry and implications for treatment. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, 62, 51–60. https://doi.org/10.1016/j.pnpbp.2015.01.001

Cui, M., Aras, R., Christian, W. V. et al (2009). The organic cation transporter-3 is a pivotal modulator of neurodegeneration in the nigrostriatal dopaminergic pathway. *Proceedings of the National Academy of Sciences of the United States of America*, 106, 8043–8048.

Cummings, J. A., Jagannathan, L., Jackson, L. R., & Becker, J. B. (2014). Sex differences in the effects of estradiol in the nucleus accumbens and striatum on the response to cocaine: Neurochemistry and behavior. *Drug and Alcohol Dependence*, 135, 22–28. https://doi.org/10.1016/j.drugalcdep.2013.09.009

Dayan, P. (2009). Dopamine, reinforcement learning, and addiction. *Pharmacopsychiatry*, 42(Suppl 1), S56–65. https://doi.org/10.1055/s-0028-1124107

delCastillo, J., & Katz, B. (1954). Quantal components of the end-plate potential. *Journal of Physiology*, *124*, 560–573. https://doi.org/10.1113/jphysiol.1954.sp005129

Denker, A., & Rizzoli, S. O. (2010). Synaptic vesicle pools: An update. *Frontiers in Synaptic Neuroscience*, *2*, 135.

Egana, L. A., Cuevas, R. A., Baust, T. B., Parra, L. A., Leak, R. K., Hochendoner, S., ... Torres, G. E. (2009). Physical and functional interaction between the dopamine transporter and the synaptic vesicle protein synaptogyrin-3. *Journal of Neuroscience*, *29*, 4592–4604. https://doi.org/10.1523/JNEUROSCI.4559-08.2009

Eiden, L. E., & Weihe, E. (2011). VMAT2: A dynamic regulator of brain monoaminergic neuronal function interacting with drugs of abuse. *Annals of the New York Academy of Sciences*, *1216*, 86–98.

Erickson, J. D., Eiden, L. E., & Hoffman, B. J. (1992). Expression cloning of a reserpine-sensitive vesicular monoamine transporter. *Proceedings of the National Academy of Sciences of the United States of America*, *89*, 10993–10997.

Ewing, A. G., Bigelow, J. C., & Wightman, R. M. (1983). Direct in vivo monitoring of dopamine released from two striatal compartments in the rat. *Science*, *221*, 169–171. https://doi.org/10.1126/science.6857277

Fagan, R. R., Kearney, P. J., Sweeney, C. G. et al (2020). Dopamine transporter trafficking and Rit2 GTPase: Mechanism of action and in vivo impact. *Journal of Biological Chemistry*, *295*, 5229–5244.

Fasano, C., Kortleven, C., & Trudeau, L. E. (2010). Chronic activation of the D2 autoreceptor inhibits both glutamate and dopamine synapse formation and alters the intrinsic properties of mesencephalic dopamine neurons in vitro. *European Journal of Neuroscience*, *32*, 1433–1441. https://doi.org/10.1111/j.1460-9568.2010.07397.x

Fawaz, C. S., Martel, P., Leo, D., & Trudeau, L.-E. (2009). Presynaptic action of neurotensin on dopamine release through inhibition of D_2 receptor function. *BMC Neuroscience*, *10*, 96.

Fennell, A. M., Pitts, E. G., Sexton, L. L., & Ferris, M. J. (2019). Phasic dopamine release magnitude tracks individual differences in sensitization of locomotor response following a history of nicotine exposure, *Scientific Reports*, *10*, 1–10.

Floor, E., Leventhal, P. S., Wang, Y., Meng, L., & Chen, W. (1995). Dynamic storage of dopamine in rat brain synaptic vesicles in vitro. *Journal of Neurochemistry*, *64*, 689–699. https://doi.org/10.1046/j.1471-4159.1995.64020689.x

Fog, J. U., Khoshbouei, H., Holy, M., Owens, W. A., Vaegter, C. B., Sen, N., ... Gether, U. (2006). Calmodulin kinase II interacts with the dopamine transporter C terminus to regulate amphetamine-induced reverse transport. *Neuron*, *51*, 417–429. https://doi.org/10.1016/j.neuron.2006.06.028

Ford, C. P. (2014). The role of D2-autoreceptors in regulating dopamine neuron activity and transmission. *Neuroscience*, *282*, 13–22. https://doi.org/10.1016/j.neuroscience.2014.01.025

Fordahl, S. C., & Jones, S. R. (2017). High-fat-diet-induced deficits in dopamine terminal function are reversed by restoring insulin signaling. *ACS Chemical Neuroscience*, *8*, 290–299. https://doi.org/10.1021/acschemneuro.6b00308

Foster, J. D., Adkins, S. D., Lever, J. R., & Vaughan, R. A. (2008). Phorbol ester induced trafficking-independent regulation and enhanced phosphorylation of the dopamine transporter associated with membrane rafts and cholesterol. *Journal of Neurochemistry*, *105*, 1683–1699. https://doi.org/10.1111/j.1471-4159.2008.05262.x

Foster, J. D., Yang, J.-W., Moritz, A. E., Challasivakanaka, S., Smith, M. A., Holy, M., ... Vaughan, R. A. (2012). Dopamine transporter phosphorylation site threonine 53 regulates substrate reuptake and amphetamine-stimulated efflux. *Journal of Biological Chemistry*, *287*, 29702–29712.

Fowler, M. A., Sidiropoulou, K., Ozkan, E. D., Phillips, C. W., & Cooper, D. C. (2007). Corticolimbic expression of TRPC4 and TRPC5 channels in the rodent brain. *PLoS ONE*, *2*, e573. https://doi.org/10.1371/journal.pone.0000573

Freed, C., Revay, R., Vaughan, R. A., Kriek, E., Grant, S., Uhl, G. R., & Kuhar, M. J. (1995). Dopamine transporter immunoreactivity in rat brain. *The Journal of Comparative Neurology*, *359*, 340–349.

Fulton, S., Thibault, D., Mendez, J. A., Lahaie, N., Tirotta, E., Borrelli, E., ... Trudeau, L.-E. (2011). Contribution of Kv1.2 voltage-gated potassium channel to D2 autoreceptor regulation of axonal dopamine overflow. *The Journal of Biological Chemistry*, *286*, 9360–9372. https://doi.org/10.1074/jbc.M110.153262

Giguère, N., Delignat-Lavaud, B., Herborg, F., Voisin, A., Li, Y., Jacquemet, V., ... Trudeau, L.-É. (2019). Increased vulnerability of nigral dopamine neurons after expansion of their axonal arborization size through D2 dopamine receptor conditional knockout. *PLoS Genetics*, *15*, e1008352–e1008352. https://doi.org/10.1371/journal.pgen.1008352

Giorguieff, M. F., Kemel, M. L., & Glowinski, J. (1977). Presynaptic effect of L-glutamic acid on the release of dopamine in rat striatal slices. *Neuroscience Letters*, *6*, 73–77. https://doi.org/10.1016/0304-3940(77)90068-4

Giros, B., & Caron, M. G. (1993). Molecular characterization of the dopamine transporter. *Trends in Pharmacological Sciences*, *14*, 43–49.

Giros, B., Jaber, M., Jones, S. R., Wightman, R. M., & Caron, M. G. (1996). Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. *Nature*, *379*, 606–612. https://doi.org/10.1038/379606a0

Gleich, T., Deserno, L., Lorenz, R. C., Boehme, R., Pankow, A., Buchert, R., ... Gallinat, J. (2015). Prefrontal and striatal glutamate differently relate to striatal dopamine: Potential regulatory mechanisms of striatal presynaptic dopamine function? *The Journal of Neuroscience*, *35*, 9615–9621. https://doi.org/10.1523/JNEUROSCI.0329-15.2015

Goda, Y., & Stevens, C. F. (1998). Readily releasable pool size changes associated with long term depression. *Proceedings of the National Academy of Sciences of the United States of America*, *95*, 1283–1288.

Gowrishankar, R., Gresch, P. J., Davis, G. L., Katamish, R. M., Riele, J. R., Stewart, A. M., ... Blakely, R. D. (2018). Region-specific regulation of presynaptic dopamine homeostasis by D_2 autoreceptors shapes the in vivo impact of the neuropsychiatric disease-associated DAT variant Val559. *The Journal of Neuroscience*, *38*, 5302–5312.

Grady, S. R., Salminen, O., Laverty, D. C., Whiteaker, P., McIntosh, J. M., Collins, A. C., & Marks, M. J. (2007). The subtypes of nicotinic acetylcholine receptors on dopaminergic terminals of mouse striatum. *Biochemical Pharmacology*, *74*, 1235–1246.

Graf, E. N., Wheeler, R. A., Baker, D. A., Ebben, A. L., Hill, J. E., McReynolds, J. R., ... Gasser, P. J. (2013). Corticosterone acts in the nucleus accumbens to enhance dopamine signaling and potentiate reinstatement of cocaine seeking. *Journal of Neuroscience*, *33*, 11800–11810. https://doi.org/10.1523/JNEUROSCI.1969-13.2013

Hamilton, P. J., Belovich, A. N., Khelashvili, G., Saunders, C., Erreger, K., Javitch, J. A., ... Galli, A. (2014). PIP2 regulates psychostimulant behaviors through its interaction with a membrane protein. *Nature Chemical Biology*, *10*, 582–589. https://doi.org/10.1038/nchembio.1545

Hanbauer, I., Wink, D., Osawa, Y., Edelman, G. M., & Gally, J. A. (1992). Role of nitric oxide in NMDA-evoked release of [3H]-dopamine from striatal slices. *NeuroReport*, *3*, 409–412. https://doi.org/10.1097/00001756-199205000-00008

Hetier, E., Boireau, A., Dubedat, P., & Blanchard, J. (1988). Neurotensin effects on evoked release of dopamine in slices from striatum, nucleus accumbens and prefrontal cortex in rat. *Naunyn-Schmiedeberg's Archives of Pharmacology*, *337*, 13–17. https://doi.org/10.1007/BF00169470

Holloway, Z. R., Freels, T. G., Comstock, J. F., Nolen, H. G., Sable, H. J., & Lester, D. B. (2019). Comparing phasic dopamine dynamics in the striatum, nucleus accumbens, amygdala, and medial prefrontal cortex. *Synapse (New York, N. Y.)*, *73*, e22074. https://doi.org/10.1002/syn.22074

Hsu, S.-F., Augustine, G. J., & Jackson, M. B. (1996). Adaptation of Ca^{2+}-triggered exocytosis in presynaptic terminals. *Neuron*, *17*, 501–512. https://doi.org/10.1016/S0896-6273(00)80182-8

Huang, Y., & Thathiah, A. (2015). Regulation of neuronal communication by G protein-coupled receptors. *FEBS Letters*, *589*, 1607–1619. https://doi.org/10.1016/j.febslet.2015.05.007

Inoue, R., Suzuki, T., Nishimura, K., & Miura, M. (2016). Nicotinic acetylcholine receptor-mediated GABAergic inputs to cholinergic interneurons in the striosomes and the matrix compartments of the mouse striatum. *Neuropharmacology*, *105*, 318–328. https://doi.org/10.1016/j.neuropharm.2016.01.029

Iversen, L. L., & Salt, P. J. (1970). Inhibition of catecholamine Uptake$_2$ by steroids in the isolated rat heart. *British Journal of Pharmacology*, *40*, 528–530.

Javoy, F., & Glowinski, J. (1971). Dynamic characteristic of the 'functional compartment' of dopamine in dopaminergic terminals of the rat striatum. *Journal of Neurochemistry*, *18*, 1305–1311.

Jiménez-Castellanos, J., & Graybiel, A. M. (1989). Compartmental origins of striatal efferent projections in the cat. *Neuroscience*, *32*, 297–321. https://doi.org/10.1016/0306-4522(89)90080-8

Johnson, A. R., Thibeault, K. C., Lopez, A. J., Peck, E. G., Sands, L. P., Sanders, C. M., ... Calipari, E. S. (2019). Cues play critical role in estrous cycle-dependent enhancement of cocaine reinforcement. *Neuropsychopharmacology.*, *44*(7), 1189–1197. https://doi.org/10.1038/s41386-019-0320-0

Jones, S. R., Gainetdinov, R. R., Hu, X.-T., Cooper, D. C., Wightman, R. M., White, F. J., & Caron, M. G. (1999). Loss of autoreceptor functions in mice lacking the dopamine transporter. *Nature Neuroscience*, *2*, 649–655. https://doi.org/10.1038/10204

Jones, S. R., Gainetdinov, R. R., Jaber, M., Giros, B., Wightman, R. M., & Caron, M. G. (1998). Profound neuronal plasticity in response to inactivation of the dopamine transporter. *Proceedings of the National Academy of Sciences of the United States of America*, *95*, 4029–4034.

Kamin, D., Lauterbach, M. A., Westphal, V., Keller, J., Schönle, A., Hell, S. W., & Rizzoli, S. O. (2010). High- and low-mobility stages in the synaptic vesicle cycle. *Biophysical Journal*, *99*, 675–684.

Karkhanis, A. N., Rose, J. H., Huggins, K. N., Konstantopoulos, J. K., & Jones, S. R. (2015). Chronic intermittent ethanol exposure reduces presynaptic dopamine neurotransmission in the mouse nucleus accumbens. *Drug and Alcohol Dependence*, *150*, 24–30. https://doi.org/10.1016/j.drugalcdep.2015.01.019

Karkhanis, A. N., Rose, J. H., Weiner, J. L., & Jones, S. R. (2016). Early-life social isolation stress increases kappa opioid receptor responsiveness and downregulates the dopamine system. *Neuropsychopharmacology*, *41*, 2263–2274. https://doi.org/10.1038/npp.2016.21

Karlin, A. (1993). Structure of nicotinic acetylcholine receptors. *Current Opinion in Neurobiology*, *3*, 299–309.

Karlin, A. (2002). Ion channel structure: Emerging structure of the nicotinic acetylcholine receptors. *Nature Reviews Neuroscience*, *3*, 102.

Katz, B. (1971). Quantal mechanism of neural transmitter release. *Science*, *173*, 123–126. https://doi.org/10.1126/science.173.3992.123

Keiflin, R., & Janak, P. H. (2015). Dopamine prediction errors in reward learning and addiction: From theory to neural circuitry. *Neuron*, *88*, 247–263. https://doi.org/10.1016/j.neuron.2015.08.037

Kennedy, R. T., Jones, S. R., & Wightman, R. M. (1992). Dynamic observation of dopamine autoreceptor effects in rat striatal slices. *Journal of Neurochemistry*, *59*, 449–455. https://doi.org/10.1111/j.1471-4159.1992.tb09391.x

Kile, B. M., Guillot, T. S., Venton, B. J., Wetsel, W. C., Augustine, G. J., & Wightman, R. M. (2010). Synapsins differentially control dopamine and serotonin release. *Journal of Neuroscience*, *30*, 9762–9770. https://doi.org/10.1523/JNEUROSCI.2071-09.2010

Kiss, J. P. (2000). Role of nitric oxide in the regulation of monoaminergic neurotransmission. *Brain research bulletin*, *52*, 459–466.

Kiss, J. P., Hennings, E. C. P., Zsilla, G., & Vizi, E. S. (1999). A possible role of nitric oxide in the regulation of dopamine transporter function in the striatum. *Neurochemistry International*, *34*, 345–350. https://doi.org/10.1016/S0197-0186(99)00019-4

Kosillo, P., Zhang, Y.-F., Threlfell, S., & Cragg, S. J. (2016). Cortical control of striatal dopamine transmission via striatal cholinergic interneurons. *Cerebral Cortex*. https://doi.org/10.1093/cercor/bhw252

Krebs, M. O., Kemel, M. L., Gauchy, C., Desban, M., & Glowinski, J. (1989). Glycine potentiates the NMDA-induced release of dopamine through a strychnine-insensitive site in the rat striatum. *European Journal of Pharmacology*, *166*, 567–570. https://doi.org/10.1016/0014-2999(89)90378-6

Krebs, M. O., Trovero, F., Desban, M., Gauchy, C., Glowinski, J., & Kemel, M. L. (1991). Distinct presynaptic regulation of dopamine release through NMDA receptors in striosome- and matrix-enriched areas of the rat striatum. *Journal of Neuroscience*, *11*, 1256–1262. https://doi.org/10.1523/JNEUROSCI.11-05-01256.1991

Kuhr, W. G., Bigelow, J. C., & Wightman, R. M. (1986). In vivo comparison of the regulation of releasable dopamine in the caudate nucleus and the nucleus accumbens of the rat brain. *The Journal of Neuroscience*, *6*, 974. https://doi.org/10.1523/JNEUROSCI.06-04-00974.1986

Kulagina, N., Zigmond, M., & Michael, A. (2001). Glutamate regulates the spontaneous and evoked release of dopamine in the rat striatum. *Neuroscience*, *102*, 121–128. https://doi.org/10.1016/S0306-4522(00)00480-2

Kutlu, M. G., Zachry, J. E., Brady, L. J., Melugin, P. R., Kelly, S. J., Sanders, C., ... Calipari, E. S. (2020). A novel multidimensional reinforcement task in mice elucidates sex-specific behavioral strategies. *Neuropsychopharmacology*. In press. https://doi.org/10.1038/s41386-020-0692-1

Kuwajima, M., Dehoff, M. H., Furuichi, T., Worley, P. F., Hall, R. A., & Smith, Y. (2007). Localization and expression of group I metabotropic glutamate receptors in the mouse striatum, globus pallidus, and subthalamic nucleus: Regulatory effects of MPTP treatment and constitutive Homer deletion. *Journal of Neuroscience*, *27*, 6249–6260. https://doi.org/10.1523/JNEUROSCI.3819-06.2007

Lammel, S., Steinberg, E. E., Földy, C., Wall, N. R., Beier, K., Luo, L., & Malenka, R. C. (2015). Diversity of transgenic mouse models for selective targeting of midbrain dopamine neurons. *Neuron*, *85*, 429–438. https://doi.org/10.1016/j.neuron.2014.12.036

Land, B. B., Bruchas, M. R., Lemos, J. C., Xu, M., Melief, E. J., & Chavkin, C. (2008). The dysphoric component of stress is encoded by activation of the dynorphin κ-opioid system. *The Journal of Neuroscience*, *28*, 407–414.

Le Merrer, J., Becker, J. A. J., Befort, K., & Kieffer, B. L. (2009). Reward processing by the opioid system in the brain. *Physiological Reviews*, *89*, 1379–1412.

Lee, F. J. S., Pei, L., Moszczynska, A., Vukusic, B., Fletcher, P. J., & Liu, F. (2007). Dopamine transporter cell surface localization facilitated by a direct interaction with the dopamine D2 receptor. *EMBO Journal*, *26*, 2127–2136. https://doi.org/10.1038/sj.emboj.7601656

Lendvai, B., & Vizi, E. S. (2008). Nonsynaptic chemical transmission through nicotinic acetylcholine receptors. *Physiological Reviews*, *88*, 333–349.

Lim, S. A. O., Kang, U. J., & McGehee, D. S. (2014). Striatal cholinergic interneuron regulation and circuit effects. *Frontiers in Synaptic Neuroscience*, *6*, 22.

Liss, B., & Roeper, J. (2010). 3.4 Ion channels and regulation of dopamine neuron activity. *Dopamine*, *handbook*, 118.

Liu, Y., & Edwards, R. H. (1997). The role of vesicular transport proteins in synaptic transmission and neural degeneration. *Annual Review of Neuroscience*, *20*, 125–156.

Liu, Y., Peter, D., Roghani, A., Schuldiner, S., Privé, G. G., Eisenberg, D., ... Edwards, R. H. (1992). A cDNA that suppresses MPP^+ toxicity

encodes a vesicular amine transporter. *Cell*, 70, 539–551. https://doi.org/10.1016/0092-8674(92)90425-C

Loder, M. K., & Melikian, H. E. (2003). The dopamine transporter constitutively internalizes and recycles in a protein kinase C-regulated manner in stably transfected PC12 cell lines. *Journal of Biological Chemistry*, 278, 22168–22174.

Lohr, K. M., Bernstein, A. I., Stout, K. A. et al (2014). Increased vesicular monoamine transporter enhances dopamine release and opposes Parkinson disease-related neurodegeneration in vivo. *Proceedings of the National Academy of Sciences of the United States of America*, 111, 9977–9982.

Lohr, K. M., Stout, K. A., Dunn, A. R., Wang, M., Salahpour, A., Guillot, T. S., & Miller, G. W. (2015). Increased vesicular monoamine transporter 2 (VMAT2; Slc18a2) protects against methamphetamine toxicity. *ACS Chemical Neuroscience*, 6, 790–799.

Lopes, E. F., Roberts, B. M., Siddorn, R. E., Clements, M. A., & Cragg, S. J. (2019). Inhibition of nigrostriatal dopamine release by striatal GABAA and GABAB receptors. *Journal of Neuroscience*, 39, 1058–1065.

Lynch, W. J., Roth, M. E., & Carroll, M. E. (2002). Biological basis of sex differences in drug abuse: Preclinical and clinical studies. *Psychopharmacology (Berl)*, 164, 121–137. https://doi.org/10.1007/s00213-002-1183-2

Ma, L., Xu, Y., Wang, G., & Li, R. (2019). What do we know about sex differences in depression: A review of animal models and potential mechanisms. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, 89, 48–56. https://doi.org/10.1016/j.pnpbp.2018.08.026

MacDermott, A. B., Mayer, M. L., Westbrook, G. L., Smith, S. J., & Barker, J. L. (1986). NMDA-receptor activation increases cytoplasmic calcium concentration in cultured spinal cord neurones. *Nature*, 321, 519–522. https://doi.org/10.1038/321519a0

Mahler, S. V., Brodnik, Z. D., Cox, B. M., Buchta, W. C., Bentzley, B. S., Quintanilla, J., ... Aston-Jones, G. (2019). Chemogenetic manipulations of ventral tegmental area dopamine neurons reveal multifaceted roles in cocaine abuse. *The Journal of Neuroscience*, 39, 503. https://doi.org/10.1523/JNEUROSCI.0537-18.2018

Maina, F. K., & Mathews, T. A. (2010). A functional fast scan cyclic voltammetry assay to characterize dopamine D2 and D3 autoreceptors in the mouse striatum. *ACS Chemical Neuroscience*, 1, 450–462.

Mansour, A., Fox, C. A., Burke, S., Meng, F., Thompson, R. C., Akil, H., & Watson, S. J. (1994). Mu, delta, and kappa opioid receptor mRNA expression in the rat CNS: An in situ hybridization study. *The Journal of Comparative Neurology*, 350, 412–438. https://doi.org/10.1002/cne.903500307

Manzoni, O., Michel, J. M., & Bockaert, J. (1997). Metabotropic glutamate receptors in the rat nucleus accumbens. *European Journal of Neuroscience*, 9, 1514–1523. https://doi.org/10.1111/j.1460-9568.1997.tb01506.x

Marchi, M., & Grilli, M. (2010). Presynaptic nicotinic receptors modulating neurotransmitter release in the Central Nervous System: Functional interactions with other coexisting receptors. *Progress in Neurobiology*, 92, 105–111. https://doi.org/10.1016/j.pneurobio.2010.06.004

Marchi, M., Risso, F., Viola, C., Cavazzani, P. & Raiteri, M. (2002) Direct evidence that release-stimulating α7* nicotinic cholinergic receptors are localized on human and rat brain glutamatergic axon terminals. *Journal of Neurochemistry*, 80, 1071–1078.

Martel, P., Leo, D., Fulton, S., Bérard, M., & Trudeau, L.-E. (2011). Role of Kv1 potassium channels in regulating dopamine release and presynaptic D2 receptor function. *PLoS ONE*, 6, e20402. https://doi.org/10.1371/journal.pone.0020402

Mayer, F. P., Schmid, D., Owens, W. A., Gould, G. G., Apuschkin, M., Kudlacek, O., ... Sitte, H. H. (2018). An unsuspected role for organic cation transporter 3 in the actions of amphetamine. *Neuropsychopharmacology*, 43, 2408–2417. https://doi.org/10.1038/s41386-018-0053-5

Mayfield, R. D., & Zahniser, N. R. (2001). Dopamine D2 receptor regulation of the dopamine transporter expressed in Xenopus laevis oocytes is voltage-independent. *Molecular Pharmacology*, 59, 113–121.

McGehee, D. S., & Role, L. W. (1995). Physiological diversity of nicotinic acetylcholine receptors expressed by vertebrate neurons. *Annual Review of Physiology*, 57, 521–546. https://doi.org/10.1146/annurev.ph.57.030195.002513

Mebel, D. M., Wong, J. C. Y., Dong, Y. J., & Borgland, S. L. (2012). Insulin in the ventral tegmental area reduces hedonic feeding and suppresses dopamine concentration via increased reuptake. *The European Journal of Neuroscience*, 36, 2336–2346. https://doi.org/10.1111/j.1460-9568.2012.08168.x

Meck, W. H. (2006). Neuroanatomical localization of an internal clock: A functional link between mesolimbic, nigrostriatal, and mesocortical dopaminergic systems. *Brain Research*, 1109, 93–107. https://doi.org/10.1016/j.brainres.2006.06.031

Meiergerd, S. M., Patterson, T. A., & Schenk, J. O. (1993). D2 receptors may modulate the function of the striatal transporter for dopamine: Kinetic evidence from studies in vitro and in vivo. *Journal of Neurochemistry*, 61, 764–767. https://doi.org/10.1111/j.1471-4159.1993.tb02185.x

Mooslehner, K. A., Chan, P. M., Xu, W., Liu, L., Smadja, C., Humby, T., ... Emson, P. C. (2001). Mice with very low expression of the vesicular monoamine transporter 2 gene survive into adulthood: Potential mouse model for parkinsonism. *Molecular and Cellular Biology*, 21, 5321–5331. https://doi.org/10.1128/MCB.21.16.5321-5331.2001

Moritz, A. E., Rastedt, D. E., Stanislowski, D. J., Shetty, M., Smith, M. A., Vaughan, R. A., & Foster, J. D. (2015). Reciprocal phosphorylation and palmitoylation control dopamine transporter kinetics. *Journal of Biological Chemistry*, 290, 29095–29105.

Morón, J. A., Zakharova, I., Ferrer, J. V., Merrill, G. A., Hope, B., Lafer, E. M., ... Shippenberg, T. S. (2003). Mitogen-activated protein kinase regulates dopamine transporter surface expression and dopamine transport capacity. *Journal of Neuroscience*, 23, 8480–8488. https://doi.org/10.1523/JNEUROSCI.23-24-08480.2003

Naef, L., Seabrook, L., Hsiao, J., Li, C., & Borgland, S. L. (2019). Insulin in the ventral tegmental area reduces cocaine-evoked dopamine in the nucleus accumbens in vivo. *European Journal of Neuroscience*, 50, 2146–2155.

Nastuk, M. A., & Graybiel, A. M. (1985). Patterns of muscarinic cholinergic binding in the striatum and their relation to dopamine islands and striosomes. *The Journal of Comparative Neurology*, 237, 176–194.

Nicot, A., Rostene, W., & Berod, A. (1994). Neurotensin receptor expression in the rat forebrain and midbrain: A combined analysis by in situ hybridization and receptor autoradiography. *The Journal of Comparative Neurology*, 341, 407–419. https://doi.org/10.1002/cne.903410310

Ovtscharoff, W., Eusterschulte, B., Zienecker, R., Reisert, I., & Pilgrim, C. (1992). Sex differences in densities of dopaminergic fibers and GABAergic neurons in the prenatal rat striatum. *Journal of Comparative Neurology*, 323, 299–304. https://doi.org/10.1002/cne.903230212

Page, G., Peeters, M., Najimi, M., Maloteaux, J.-M., & Hermans, E. (2001). Modulation of the neuronal dopamine transporter activity by the metabotropic glutamate receptor mGluR5 in rat striatal synaptosomes through phosphorylation mediated processes. *Journal of Neurochemistry*, 76, 1282–1290. https://doi.org/10.1046/j.1471-4159.2001.00179.x

Palacios, J. M., & Kuhar, M. J. (1981). Neurotensin receptors are located on dopamine-containing neurones in rat midbrain. *Nature*, 294, 587–589. https://doi.org/10.1038/294587a0

Palij, P., Bull, D. R., Sheehan, M. J., Millar, J., Stamford, J., Kruk, Z. L., & Humphrey, P. P. (1990). Presynaptic regulation of dopamine release in corpus striatum monitored in vitro in real time by fast cyclic voltammetry. *Brain Research*, 509, 172–174. https://doi.org/10.1016/0006-8993(90)90329-A

Paquet, M., & Smith, Y. (2003). Group I metabotropic glutamate receptors in the monkey striatum: Subsynaptic association with glutamatergic and dopaminergic afferents. *The Journal of Neuroscience*, *23*, 7659–7669. https://doi.org/10.1523/JNEUROSCI.23-20-07659.2003

Parish, C. L., Finkelstein, D. I., Drago, J., Borrelli, E., & Horne, M. K. (2001). The role of dopamine receptors in regulating the size of axonal arbors. *Journal of Neuroscience*, *21*, 5147–5157. https://doi.org/10.1523/JNEUROSCI.21-14-05147.2001

Parish, C. L., Stanic, D., Drago, J., Borrelli, E., Finkelstein, D. I., & Horne, M. K. (2002). Effects of long-term treatment with dopamine receptor agonists and antagonists on terminal arbor size. *European Journal of Neuroscience*, *16*, 787–794. https://doi.org/10.1046/j.1460-9568.2002.02132.x

Patel, J., Mooslehner, K. A., Chan, P. M., Emson, P. C., & Stamford, J. A. (2003). Presynaptic control of striatal dopamine neurotransmission in adult vesicular monoamine transporter 2 (VMAT2) mutant mice. *Journal of Neurochemistry*, *85*, 898–910. https://doi.org/10.1046/j.1471-4159.2003.01732.x

Pellmar, T. C. (1987). Peroxide alters neuronal excitability in the CA1 region of guinea-pig hippocampus in vitro. *Neuroscience*, *23*, 447–456. https://doi.org/10.1016/0306-4522(87)90068-6

Pennartz, C. M., Groenewegen, H. J., & Lopes da Silva, F. H. (1994). The nucleus accumbens as a complex of functionally distinct neuronal ensembles: An integration of behavioural, electrophysiological and anatomical data. *Progress in Neurobiology*, *42*, 719–761. https://doi.org/10.1016/0301-0082(94)90025-6

Phillips, P. E. M., Hancock, P. J., & Stamford, J. A. (2002). Time window of autoreceptor-mediated inhibition of limbic and striatal dopamine release. *Synapse (New York, N. Y.)*, *44*, 15–22. https://doi.org/10.1002/syn.10049

Phillips, P. E., & Stamford, J. A. (2000). Differential recruitment of N-, P- and Q-type voltage-operated calcium channels in striatal dopamine release evoked by 'regular' and 'burst' firing. *Brain Research*, *884*, 139–146. https://doi.org/10.1016/S0006-8993(00)02958-9

Picciotto, M. R., Zoli, M., Rimondini, R., Léna, C., Marubio, L. M., Pich, E. M., … Changeux, J. P. (1998). Acetylcholine receptors containing the beta2 subunit are involved in the reinforcing properties of nicotine. *Nature*, *391*, 173–177.

Pitman, K. A., Puil, E., & Borgland, S. L. (2014). GABA(B) modulation of dopamine release in the nucleus accumbens core. *European Journal of Neuroscience*, *40*, 3472–3480.

Pogun, S., Baumann, M. H., & Kuhar, M. J. (1994). Nitric oxide inhibits [3H]dopamine uptake. *Brain Research*, *641*, 83–91. https://doi.org/10.1016/0006-8993(94)91818-X

Pothos, E. N., Davila, V., & Sulzer, D. (1998). Presynaptic recording of quanta from midbrain dopamine neurons and modulation of the quantal size. *Journal of Neuroscience*, *18*, 4106–4118. https://doi.org/10.1523/JNEUROSCI.18-11-04106.1998

Pothos, E. N., Larsen, K. E., Krantz, D. E., Liu, Y., Haycock, J. W., Setlik, W., … Sulzer, D. (2000). Synaptic vesicle transporter expression regulates vesicle phenotype and quantal size. *Journal of Neuroscience*, *20*, 7297–7306. https://doi.org/10.1523/JNEUROSCI.20-19-07297.2000

Quik, M., Bordia, T., & O'Leary, K. (2007). Nicotinic receptors as CNS targets for Parkinson's disease. *Biochemical Pharmacology*, *74*, 1224–1234.

Quirion, R., Chiueh, C. C., Everist, H. D., & Pert, A. (1985). Comparative localization of neurotensin receptors on nigrostriatal and mesolimbic dopaminergic terminals. *Brain Research*, *327*, 385–389. https://doi.org/10.1016/0006-8993(85)91542-2

Ramsson, E. S., Howard, C. D., Covey, D. P., & Garris, P. A. (2011). High doses of amphetamine augment, rather than disrupt, exocytotic dopamine release in the dorsal and ventral striatum of the anesthetized rat. *Journal of Neurochemistry*, *119*, 1162–1172. https://doi.org/10.1111/j.1471-4159.2011.07407.x

Rice, M. E. (2011). H2O2: A dynamic neuromodulator. *The Neuroscientist: A Review Journal Bringing Neurobiology, Neurology and Psychiatry*, *17*, 389–406.

Rice, M. E., & Cragg, S. J. (2004). Nicotine amplifies reward-related dopamine signals in striatum. *Nature Neuroscience*, *7*, 583–584.

Richards, D. A., Guatimosim, C., Rizzoli, S. O., & Betz, W. J. (2003). Synaptic vesicle pools at the frog neuromuscular junction. *Neuron*, *39*, 529–541. https://doi.org/10.1016/S0896-6273(03)00405-7

Richardson, B. D., Saha, K., Krout, D. et al (2016). Membrane potential shapes regulation of dopamine transporter trafficking at the plasma membrane. *Nature Communications*, *7*, 10423.

Rizzoli, S. O., & Betz, W. J. (2005). Synaptic vesicle pools. *Nature Reviews Neuroscience*, *6*, 57–69.

Roberts, D. C. S., Corcoran, M. E., & Fibiger, H. C. (1977). On the role of ascending catecholaminergic systems in intravenous self-administration of cocaine. *Pharmacology Biochemistry and Behavior*, *6*, 615–620. https://doi.org/10.1016/0091-3057(77)90084-3

Ronken, E., Mulder, A., & Schoffelmeer, A. (1993a). Interacting presynaptic k-opioid and GABAa receptors modulate dopamine release from rat striatal synaptosomes. *Journal of Neurochemistry*, *61*, 1634–1639.

Ronken, E., Mulder, A. H., & Schoffelmeer, A. N. (1993b). Interacting presynaptic kappa-opioid and GABAA receptors modulate dopamine release from rat striatal synaptosomes. *Journal of Neurochemistry*, *61*, 1634–1639.

Rothblat, D. S., & Schneider, J. S. (1997). Regionally specific effects of haloperidol and clozapine on dopamine reuptake in the striatum. *Neuroscience Letters*, *228*, 119–122.

Rothman, R. B., Baumann, M. H., Dersch, C. M., Romero, D. V., Rice, K. C., Carroll, F. I., & Partilla, J. S. (2001). Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. *Synapse (New York, N. Y.)*, *39*, 32–41. https://doi.org/10.1002/1098-2396(20010101)39:1<32::AID-SYN5>3.0.CO;2-3

Rouge-Pont, F., Usiello, A., Benoit-Marand, M., Gonon, F., Piazza, P. V., & Borrelli, E. (2002). Changes in extracellular dopamine induced by morphine and cocaine: Crucial control by D2 receptors. *Journal of Neuroscience*, *22*, 3293–3301. https://doi.org/10.1523/JNEUROSCI.22-08-03293.2002

Russo, S. J., & Nestler, E. J. (2013). The brain reward circuitry in mood disorders. *Nature Reviews Neuroscience*, *14*, 609–625. https://doi.org/10.1038/nrn3381

Sacaan, A. I., Bymaster, F. P., & Schoepp, D. D. (1992). Metabotropic glutamate receptor activation produces extrapyramidal motor system activation that is mediated by striatal dopamine. *Journal of Neurochemistry*, *59*, 245–251. https://doi.org/10.1111/j.1471-4159.1992.tb08897.x

Salamone, A., Zappettini, S., Grilli, M., Olivero, G., Agostinho, P., Tomé, A. R., … Marchi, M. (2014). Prolonged nicotine exposure down-regulates presynaptic NMDA receptors in dopaminergic terminals of the rat nucleus accumbens. *Neuropharmacology*, *79*, 488–497. https://doi.org/10.1016/j.neuropharm.2013.12.014

Salminen, O., Murphy, K. L., McIntosh, J. M., Drago, J., Marks, M. J., Collins, A. C., & Grady, S. R. (2004). Subunit composition and pharmacology of two classes of striatal presynaptic nicotinic acetylcholine receptors mediating dopamine release in mice. *Molecular Pharmacology*, *65*, 1526–1535.

Sandor, N. T., Brassai, A., Pliskas, A., & Lendvai, B. (1995). Role of nitric oxide in modulating neurotransmitter release from rat striatum. *Brain Research Bulletin*, *36*, 483–486. https://doi.org/10.1016/0361-9230(94)00229-T

Schmitz, Y., Benoit-Marand, M., Gonon, F., & Sulzer, D. (2003). Presynaptic regulation of dopaminergic neurotransmission. *Journal of Neurochemistry*, *87*, 273–289. https://doi.org/10.1046/j.1471-4159.2003.02050.x

Schmitz, Y., Schmauss, C., & Sulzer, D. (2002). Altered dopamine release and uptake kinetics in mice lacking D2 receptors. *Journal of Neuroscience*, 22, 8002–8009.

Schotte, A., & Leysen, J. E. (1989). Autoradiographic evidence for the localization of high affinity neurotensin binding sites on dopaminergic nerve terminals in the nigrostriatal and mesolimbic pathways in rat brain. *Journal of Chemical Neuroanatomy*, 2, 253–257.

Schuldiner, S., Shirvan, A., & Linial, M. (1995). Vesicular neurotransmitter transporters: From bacteria to humans. *Physiological Reviews*, 75, 369–392. https://doi.org/10.1152/physrev.1995.75.2.369

Schultz, W., Dayan, P., & Montague, P. R. (1997). A Neural substrate of prediction and reward. *Science*, 275, 1593–1599. https://doi.org/10.1126/science.275.5306.1593

Segovia, G., & Mora, F. (2001). Involvement of NMDA and AMPA/kainate receptors in the effects of endogenous glutamate on extracellular concentrations of dopamine and GABA in the nucleus accumbens of the awake rat. *Brain Research Bulletin*, 54, 153–157. https://doi.org/10.1016/S0361-9230(00)00432-9

Séguéla, P., Wadiche, J., Dineley-Miller, K., Dani, J. A., & Patrick, J. W. (1993). Molecular cloning, functional properties, and distribution of rat brain alpha 7: A nicotinic cation channel highly permeable to calcium. *Journal of Neuroscience*, 13, 596–604. https://doi.org/10.1523/JNEUROSCI.13-02-00596.1993

Shin, J. H., Adrover, M. F., & Alvarez, V. A. (2017). Distinctive modulation of dopamine release in the nucleus accumbens shell mediated by dopamine and acetylcholine receptors. *Journal of Neuroscience*, 37, 11166–11180. https://doi.org/10.1523/JNEUROSCI.0596-17.2017

Shore, P. A. (1976). Actions of amfonelic acid and other non-amphetamine stimulants on the dopamine neuron. *Journal of Pharmacy and Pharmacology*, 28, 855–857.

Shu, Z., Taylor, I. M., & Michael, A. C. (2013). The dopamine patchwork of the rat nucleus accumbens core. *European Journal of Neuroscience*, 38, 3221–3229.

Siciliano, C. A. (2019). Capturing the complexity of sex differences requires multidimensional behavioral models. *Neuropsychopharmacology*, 44, 1997–1998. https://doi.org/10.1038/s41386-019-0424-6

Siciliano, C. A., Calipari, E. S., Cuzon Carlson, V. C., Helms, C. M., Lovinger, D. M., Grant, K. A., & Jones, S. R. (2015). Voluntary ethanol intake predicts κ-opioid receptor supersensitivity and regionally distinct dopaminergic adaptations in macaques. *Journal of Neuroscience*, 35, 5959–5968. https://doi.org/10.1523/JNEUROSCI.4820-14.2015

Siciliano, C. A., Calipari, E. S., & Jones, S. R. (2014). Amphetamine potency varies with dopamine uptake rate across striatal subregions. *Journal of Neurochemistry*, 131, 348–355. https://doi.org/10.1111/jnc.12808

Siciliano, C. A., McIntosh, J. M., Jones, S. R., & Ferris, M. J. (2017). α6β2 Subunit containing nicotinic acetylcholine receptors exert opposing actions on rapid dopamine signaling in the nucleus accumbens of rats with high-versus low-response to novelty. *Neuropharmacology*, 126, 281–291. https://doi.org/10.1016/j.neuropharm.2017.06.028

Spanos, M., Gras-Najjar, J., Letchworth, J. M., Sanford, A. L., Toups, J. V., & Sombers, L. A. (2013). Quantitation of hydrogen peroxide fluctuations and their modulation of dopamine dynamics in the rat dorsal striatum using fast-scan cyclic voltammetry. *ACS Chemical Neuroscience*, 4, 782–789. https://doi.org/10.1021/cn4000499

Steiner, H., & Gerfen, C. R. (1996). Dynorphin regulates D1 dopamine receptor-mediated responses in the striatum: Relative contributions of pre- and postsynaptic mechanisms in dorsal and ventral striatum demonstrated by altered immediate-early gene induction. *The Journal of Comparative Neurology*, 376, 530–541. https://doi.org/10.1002/(SICI)1096-9861(19961223)376:4<530:AID-CNE3>3.0.CO;2-2

Steiner, H., & Gerfen, C. R. (1998). Role of dynorphin and enkephalin in the regulation of striatal output pathways and behavior. *Experimental Brain Research*, 123, 60–76. https://doi.org/10.1007/s002210050545

Stevens, C. F., & Wesseling, J. F. (1998). Activity-dependent modulation of the rate at which synaptic vesicles become available to undergo exocytosis. *Neuron*, 21, 415–424. https://doi.org/10.1016/S0896-6273(00)80550-4

Stouffer, M. A., Woods, C. A., Patel, J. C., Lee, C. R., Witkovsky, P., Bao, L. I., ... Rice, M. E. (2015). Insulin enhances striatal dopamine release by activating cholinergic interneurons and thereby signals reward. *Nature Communications*, 6, 8543. https://doi.org/10.1038/ncomms9543

Svingos, A. L., Chavkin, C., Colago, E. E., & Pickel, V. M. (2001). Major coexpression of kappa-opioid receptors and the dopamine transporter in nucleus accumbens axonal profiles. *Synapse (New York, N. Y.)*, 42, 185–192.

Svingos, A. L., Colago, E. E., & Pickel, V. M. (1999). Cellular sites for dynorphin activation of kappa-opioid receptors in the rat nucleus accumbens shell. *Journal of Neuroscience*, 19, 1804–1813.

Sweeney, C. G., Kearney, P. J., Fagan, R. R., Smith, L. A., Bolden, N. C., Zhao-Shea, R., ... Melikian, H. E. (2020). Conditional, inducible gene silencing in dopamine neurons reveals a sex-specific role for Rit2 GTPase in acute cocaine response and striatal function. *Neuropsychopharmacology*, 45, 384–393. https://doi.org/10.1038/s41386-019-0457-x

Sweeney, C. G., Tremblay, B. P., Stockner, T., Sitte, H. H., & Melikian, H. E. (2017). Dopamine transporter amino and carboxyl termini synergistically contribute to substrate and inhibitor affinities. *Journal of Biological Chemistry*, 292, 1302–1309. https://doi.org/10.1074/jbc.M116.762872

Thanawala, M. S., & Regehr, W. G. (2013). Presynaptic calcium influx controls neurotransmitter release in part by regulating the effective size of the readily releasable pool. *Journal of Neuroscience*, 33, 4625–4633. https://doi.org/10.1523/JNEUROSCI.4031-12.2013

Thompson, A. C., Zapata, A., Justice, J. B., Vaughan, R. A., Sharpe, L. G., & Shippenberg, T. S. (2000). κ-Opioid receptor activation modifies dopamine uptake in the nucleus accumbens and opposes the effects of cocaine. *The Journal of Neuroscience*, 20(24), 9333–9340. https://doi.org/10.1523/JNEUROSCI.20-24-09333.2000

Threlfell, S., & Cragg, S. J. (2011). Dopamine signaling in dorsal versus ventral striatum: The dynamic role of cholinergic interneurons. *Frontiers in Systems Neuroscience*, 5, 11. https://doi.org/10.3389/fnsys.2011.00011

Threlfell, S., Lalic, T., Platt, N. J., Jennings, K. A., Deisseroth, K., & Cragg, S. J. (2012). Striatal dopamine release is triggered by synchronized activity in cholinergic interneurons. *Neuron*, 75, 58–64. https://doi.org/10.1016/j.neuron.2012.04.038

Townsend, E. A., Negus, S. S., Caine, S. B., Thomsen, M., & Banks, M. L. (2019). Sex differences in opioid reinforcement under a fentanyl vs. food choice procedure in rats. *Neuropsychopharmacology*, 44, 2022–2029. https://doi.org/10.1038/s41386-019-0356-1

Tripanichkul, W., Stanic, D., Drago, J., Finkelstein, D. I., & Horne, M. K. (2003). D2 Dopamine receptor blockade results in sprouting of DA axons in the intact animal but prevents sprouting following nigral lesions. *European Journal of Neuroscience*, 17, 1033–1045.

Turner, T. J. (2004). Nicotine enhancement of dopamine release by a calcium-dependent increase in the size of the readily releasable pool of synaptic vesicles. *Journal of Neuroscience*, 24, 11328–11336. https://doi.org/10.1523/JNEUROSCI.1559-04.2004

Uhl, G. R., & Kitayama, S. (1993). A cloned dopamine transporter. Potential insights into Parkinson's disease pathogenesis. *Advances in Neurology*, 60, 321–324.

Venton, B. J., Seipel, A. T., Phillips, P. E. M., Wetsel, W. C., Gitler, D., Greengard, P., ... Wightman, R. M. (2006). Cocaine increases dopamine release by mobilization of a synapsin-dependent reserve pool. *Journal of Neuroscience*, 26, 3206–3209. https://doi.org/10.1523/JNEUROSCI.4901-04.2006

Verheij, M. M. M., & Cools, A. R. (2011). Reserpine differentially affects cocaine-induced behavior in low and high responders to novelty. *Pharmacology, Biochemistry and Behavior, 98*, 43–53.

Verheij, M. M. M., deMulder, E. L. W., De Leonibus, E., van Loo, K. M. J., & Cools, A. R. (2008). Rats that differentially respond to cocaine differ in their dopaminergic storage capacity of the nucleus accumbens. *Journal of Neurochemistry, 105*, 2122–2133. https://doi.org/10.1111/j.1471-4159.2008.05323.x

Vincent, S. R. (2010). Nitric oxide neurons and neurotransmission. *Progress in Neurobiology, 90*, 246–255. https://doi.org/10.1016/j.pneurobio.2009.10.007

Walker, Q. D., Ray, R., & Kuhn, C. M. (2006). Sex differences in neurochemical effects of dopaminergic drugs in rat striatum. *Neuropsychopharmacology, 31*, 1193–1202. https://doi.org/10.1038/sj.npp.1300915

Walker, Q. D., Rooney, M. B., Wightman, R. M., & Kuhn, C. M. (2000). Dopamine release and uptake are greater in female than male rat striatum as measured by fast cyclic voltammetry. *Neuroscience, 95*, 1061–1070. https://doi.org/10.1016/S0306-4522(99)00500-X

Wang, L. Y., & Kaczmarek, L. K. (1998). High-frequency firing helps replenish the readily releasable pool of synaptic vesicles. *Nature, 394*, 384–388. https://doi.org/10.1038/28645

Wang, X., Pinter, M. J., & Rich, M. M. (2016). Reversible recruitment of a homeostatic reserve pool of synaptic vesicles underlies rapid homeostatic plasticity of quantal content. *Journal of Neuroscience, 36*, 828–836. https://doi.org/10.1523/JNEUROSCI.3786-15.2016

Wang, Y.-M., Gainetdinov, R. R., Fumagalli, F., Xu, F., Jones, S. R., Bock, C. B., ... Caron, M. G. (1997). Knockout of the vesicular monoamine transporter 2 gene results in neonatal death and supersensitivity to cocaine and amphetamine. *Neuron, 19*, 1285–1296. https://doi.org/10.1016/S0896-6273(00)80419-5

Watabe-Uchida, M., Eshel, N., & Uchida, N. (2017). Neural circuitry of reward prediction error. *Annual Review of Neuroscience, 40*, 373–394. https://doi.org/10.1146/annurev-neuro-072116-031109

Watson, F., Kiernan, R. S., Deavall, D. G., Varro, A., & Dimaline, R. (2001). Transcriptional activation of the rat vesicular monoamine transporter 2 promoter in gastric epithelial cells: Regulation by gastrin. *Journal of Biological Chemistry, 276*, 7661–7671.

Wei, Y., Williams, J. M., Dipace, C., Sung, U., Javitch, J. A., Galli, A., & Saunders, C. (2007). Dopamine transporter activity mediates amphetamine-induced inhibition of Akt through a Ca^{2+}/calmodulin-dependent kinase II-dependent mechanism. *Molecular Pharmacology, 71*, 835–842.

Werther, G. A., Hogg, A., Oldfield, B. J., McKinley, M. J., Figdor, R., Allen, A. M., & Mendelsohn, F. A. (1987). Localization and characterization of insulin receptors in rat brain and pituitary gland using in vitro autoradiography and computerized densitometry. *Endocrinology, 121*, 1562–1570.

Wescott, S. A., Rauthan, M., & Xu, X. Z. S. (2013). When a TRP goes bad: Transient receptor potential channels in addiction. *Life Sciences, 92*, 410–414. https://doi.org/10.1016/j.lfs.2012.07.008

West, A. R., Galloway, M. P., & Grace, A. A. (2002). Regulation of striatal dopamine neurotransmission by nitric oxide: Effector pathways and signaling mechanisms. *Synapse (New York, N. Y.), 44*, 227–245. https://doi.org/10.1002/syn.10076

White, J. F., Noinaj, N., Shibata, Y., Love, J., Kloss, B., Xu, F., ... Grisshammer, R. (2012). Structure of the agonist-bound neurotensin receptor. *Nature, 490*, 508–513. https://doi.org/10.1038/nature11558

Wu, Y., Pearl, S. M., Zigmond, M. J., & Michael, A. C. (2000). Inhibitory glutamatergic regulation of evoked dopamine release in striatum. *Neuroscience, 96*, 65–72. https://doi.org/10.1016/S0306-4522(99)00539-4

Yao, J., Erickson, J. D., & Hersh, L. B. (2004). Protein kinase A affects trafficking of the vesicular monoamine transporters in PC12 cells. *Traffic, 5*, 1006–1016. https://doi.org/10.1111/j.1600-0854.2004.00240.x

Yavas, E., & Young, A. M. J. (2017). *N*-methyl-D-aspartate modulation of nucleus accumbens dopamine release by metabotropic glutamate receptors: Fast cyclic voltammetry studies in rat brain slices in vitro. *ACS Chemical Neuroscience, 8*, 320–328.

Yavich, L., & MacDonald, E. (2000). Dopamine release from pharmacologically distinct storage pools in rat striatum following stimulation at frequency of neuronal bursting. *Brain Research, 870*, 73–79. https://doi.org/10.1016/S0006-8993(00)02403-3

Yoest, K. E., Quigley, J. A., & Becker, J. B. (2018). Rapid effects of ovarian hormones in dorsal striatum and nucleus accumbens. *Hormones and Behavior, 104*, 119–129.

Yorgason, J. T., Zeppenfeld, D. M., & Williams, J. T. (2017). Cholinergic interneurons underlie spontaneous dopamine release in nucleus accumbens. *Journal of Neuroscience, 37*, 2086–2096. https://doi.org/10.1523/JNEUROSCI.3064-16.2017

Zhang, H., & Sulzer, D. (2003). Glutamate spillover in the striatum depresses dopaminergic transmission by activating group I metabotropic glutamate receptors. *Journal of Neuroscience, 23*, 10585–10592. https://doi.org/10.1523/JNEUROSCI.23-33-10585.2003

Zhang, H., & Sulzer, D. (2004). Frequency-dependent modulation of dopamine release by nicotine. *Nature Neuroscience, 7*, 581–582.

Zhang, H., & Sulzer, D. (2012). Regulation of striatal dopamine release by presynaptic auto- and heteroreceptors. *Basal Ganglia, 2*, 5–13. https://doi.org/10.1016/j.baga.2011.11.004

Zhen, J., Reith, M. E. A., & Carr, K. D. (2006). Chronic food restriction and dopamine transporter function in rat striatum. *Brain Research, 1082*, 98–101. https://doi.org/10.1016/j.brainres.2006.01.094